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Discovery of Genetic Mechanisms Underlying Inter-Individual 
Differences in Allopurinol Response 
Deanna Brackman 
Abstract 
Reverse translational research takes a bedside to bench approach, using sophisticated 
basic research to explain the biological mechanisms behind observed clinical data. 
Here, we used this approach to characterize the inter-individual differences in the 
efficacy and pharmacokinetics of a commonly prescribed drug, allopurinol. Allopurinol is 
the first-line treatment for chronic gout, a debilitating arthritis caused by high serum uric 
acid levels. Not only is the prevalence of gout growing rapidly, but high serum uric acid 
and gout have been shown to be important risk factors for the development of 
comorbidities such as renal and cardiovascular disease. Thus, allopurinol is increasingly 
being used in preventing these deadly diseases.  However, response to allopurinol is 
variable, and many gout patients fail to achieve healthy serum uric acid levels, even 
while adherent. This failure could be due to a number of reasons, including dosing, 
renal function, or the focus of this dissertation, genetics. Our reverse translational 
approach begins with the largest genome-wide association study on allopurinol 
response to date, performed in a multi-ethnic cohort of patients taking allopurinol for the 
treatment of gout. Consistent with previous studies, we observed that the Q141K variant 
in ABCG2 (rs2231142), which encodes the efflux pump BCRP, associated with worse 
response to allopurinol.  However, for the first time this association reached genome-
wide level significance (p=8.06 x 10-11).  Additionally, we identified a novel association 
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with a variant in GREM2 (rs1934341, p=3.2 x 10-6) that associates with better response. 
In vitro studies led to the identification of oxypurinol, the active metabolite of allopurinol, 
as an inhibitor of the uric acid transporter GLUT9, suggesting that oxypurinol may 
modulate uric acid disposition. These results suggest that allopurinol may have 
additional hypouricemic effects beyond xanthine oxidase inhibition, a mechanism 
previously unknown.  In order to further explore the role between BCRP Q141K and 
allopurinol response, we performed a clinical study in which we characterized the 
relationship between BCRP Q141K and allopurinol pharmacokinetics and 
pharmacodynamics in 19 healthy volunteers. We observed a significantly longer 
oxypurinol half-life in subjects harboring the Q141K variant (19.1 ± 0.5 vs 23.3 ± 0.2, 
p=0.02), but no differences in any other pharmacokinetic parameters. These results 
suggest that the association between response and BCRP Q141K may be dependent 
on tissue levels of the drug, rather than systemic levels. These findings have important 
implications in the understanding of allopurinol’s mechanism of action and clinical use, 
and more broadly, for the complex relationships between BCRP Q141K and the 
pharmacokinetics of its substrates.  
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Chapter 1: Reverse Translational Research of ABCG2 (BCRP) in Human Disease 
and Drug Response 
Abstract 
Reverse translational research takes a bedside‐to‐bench approach, using sophisticated 
basic research to explain the biological mechanisms behind observed clinical data. For 
transporters, which play a role in human disease and drug response, this approach 
offers a distinct advantage over the typical translational research, which often falters 
due to inadequate in vitro and preclinical animal models. Research on ABCG2, which 
encodes the Breast Cancer Resistance Protein, has benefited immensely from a 
reverse translational approach due to its broad implications for disease susceptibility 
and both therapeutic and adverse drug response. In this review, we describe the 
success of reverse translational research for ABCG2 and opportunities for further 
studies. 
 
Introduction 
Translational research generally takes a bench to bedside approach, in which laboratory 
research is translated to address pertinent problems in the clinic.  This approach has led 
to a wealth of new information about human physiology and pathophysiology.   
However, the approach falters in one key area: the discovery and development of new 
drug therapies.   What is often described as the “valley of death,” refers to the large gap 
between the number of potential drug targets identified through laboratory research year 
and the number of new therapies on the market. Notably, budgets of the top 10 
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pharmaceutical companies totaled $70.5 billion in 2016, with only 22 new drugs being 
approved by the FDA in the same year (1, 2).  
 
So why has translational research failed to result in more approved prescription drugs?  
The leading cause for failure of drugs in phase II and III clinical trials is lack of efficacy, 
followed by lack of safety and market need (3).  Lack of efficacy can be attributed to the 
failure of methods used in drug development to reliably predict therapeutic drug 
response. For example, cell based research fails to fully recapitulate the complexity of 
the human body as a whole system whereas large differences in pharmacologic action 
between humans and preclinical animal species may result in false predictions of drug 
response.   Further, differences in drug metabolism and transport among species may 
result in poor predictions of pharmacokinetics, which in turn may lead to lack of efficacy 
or safety in clinical trials.  Because of these species differences, drug developers are 
increasingly relying on human genetic data as well as in vitro assays from human cells. 
In vitro drug metabolism studies are typically performed in primary or cryopreserved 
hepatocyte cultures and microsomes derived from human liver.  However, hepatocytes 
lose much of their canalicular drug transporters during culture and undergo substantial 
de-differentiation when plated (4, 5). The artificial environment of the system also has 
no flow or shear stress, which has been shown to affect transporter expression in mice 
(6).  
 
Increasingly, a vast amount of human data has been extracted and stored in publicly 
accessible databases, providing an enabling resource for reverse translation.   Reverse 
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translational research offers a complementary approach to traditional translational 
research.  In particular, in reverse translation, the challenge for the researcher is to 
explain the observational data through detailed and in depth mechanistic studies, 
reproducing clinical findings in preclinical in vitro or in vivo models that can then be used 
for further translational research.  This kind of research is especially powerful in the 
context of drug development, as it not only improves the safety and efficacy of newly 
developed drugs but also identifies potential new targets or clinical subtypes of disease 
that can inform future drug development. With the increasing availability of 
computational tools and decreasing costs of high-throughput genetic screens, reverse 
translational research has become a mainstay of human genetic studies, and is 
becoming an important tool in discovering the endogenous role of proteins as well.  
 
Against this backdrop reverse translational research in the area of membrane 
transporters has advanced rapidly.  Traditionally, membrane transporters have been of 
particular interest to drug developers because of their multiple roles in drug toxicity and 
pharmacokinetics.  However, more recently, transporters have increasingly been 
recognized as enticing drug targets, as human genetic studies have revealed their roles 
in the pathophysiology of both rare and common disease (7). For example, genome-
wide association studies focused on serum uric acid levels have revealed an essential 
role for URAT1 (SLC22A12) in hyperuricemia, and supported the development of a new 
drug targeted to the transporter (lesinurad) in the treatment of gout (8).  Another 
transporter revealed in genome-wide association studies for its association with uric 
acid levels is the ATP-Binding Cassette protein, ABCG2, which encodes Breast Cancer 
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Resistance Protein (BCRP).  This efflux transporter, which contributes to the disposition 
of various drugs and endogenous solutes such as uric acid, estrone sulfates, and folic 
acid, is of broad interest in drug development.   Here, we describe the successes of 
reverse translational research for this transporter, and include future directions for the 
potential of translating research on BCRP into diagnostic and therapeutic products.    
 
The Discovery and Characterization of ABCG2 
Because of its wide expression, broad substrate specificity, and complex regulation, 
BCRP plays an important role in a number of endogenous pathways as well as 
xenobiotic metabolism and excretion.  Reverse translational research has made a 
significant impact on the understanding the diverse roles of BCRP.  Importantly, the 
discovery of BCRP itself has its own roots in reverse translation. Unlike the discovery of 
many other proteins including transporters, which typically occurred in rodents followed 
by identification of human orthologs, BCRP was cloned directly from a human breast 
cancer cell line selected for multi-drug resistance, as described below. 
 
In the late 1970s, the discoveries of P-glycoprotein (P-gp, ABCB1) and Multi-drug 
Resistance Associated Protein (MRP, ABCC) introduced the idea of broad-spectrum 
xenobiotic efflux proteins that could induce multi-drug resistance, and sparked a new 
wave of research focused on improving current chemotherapies. However, these 
transporters alone could not account for the spectrum of multi-drug resistant cancers 
seen in the clinic (9). One trial dosed 41 EPOCH-resistant Non-Hodgkin’s lymphoma 
patients with both dexverapamil, a potent P-gp inhibitor, and EPOCH chemotherapy. 
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The results showed only a moderate response in 3 patients (7%), and concluded that P-
gp inhibition was insufficient to reverse drug resistance in Non-Hodgkin’s lymphoma 
(10). Another study of verapamil, another P-gp inhibitor, and chemotherapy in 
previously untreated small cell lung cancer yielded similar results, with no significant 
difference between the control and verapamil treatment groups (11).  
 
These results, taken with many other instances of P-gp inhibitors falling short in the 
clinic, indicated other mechanisms by which tumors induced multi-drug resistance. 
Using MCF-7 cells that exhibited resistance to both adriamycin and verapamil, Doyle, et 
al used RNA fingerprinting to identify a novel 72 kDa protein, thus the discovery of 
Breast Cancer Resistance Protein (12).  This finding was quickly replicated in other 
human cell lines, including colon carcinoma S1, gastric carcinoma EPG-85-257, and 
fibrosarcoma EPF86-079 cells (9). In fact, two of these replications were so soon after 
the discovery of BCRP that they were thought to be novel findings and the protein was 
given the names ABCP (ATP-Binding Cassette Placenta) and MXR (Mitoxantrone 
Resistance) (13). Today, we refer to the protein by its original name, BCRP.   
 
BCRP has since been characterized as a half-transporter, requiring the formation of a 
homodimer by disulfide bridges to form a fully functional transporter. Similar to other 
human ABC transporters, BCRP functions as an efflux transporter, using ATP-
hydrolysis to pump its substrates against the concentration gradient and protect tissues 
from harmful metabolites and xenobiotics. In addition to variable expression in tumors, 
BCRP is expressed on the apical cell membranes of the placenta, brain, prostate, 
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gastrointestinal tract, testes, ovaries, hepatocytes, renal tubules, stem cells, adrenal 
gland, uterus, bile ducts, gallbladder, central nervous system, and endothelium of veins 
and capillaries.  Many factors are involved in the regulation of BCRP expression and 
activity, such as cholesterol content, promoter methylation, and estrogen response 
elements (13, 14). 
 
ABCG2 Polymorphisms 
Though a number of single nucleotide polymorphisms (SNPs) are present in the ABCG2 
gene, one SNP in particular has garnered much interest because of its high prevalence 
in Japanese and Chinese populations and its reduced function. ABCG2 c.421C>A 
(BCRP Q141K) encodes a change from glutamine to lysine at the 141st amino acid of 
the BCRP protein, and has an allele frequency ranging from 22 to 34% in East Asian 
populations (15). This missense codon does not alter mRNA levels of BCRP; rather, it 
increases the lysosomal breakdown of the protein from the endoplasmic reticulum. 
Studies suggest that this is due to instability in the nucleotide-binding domain, which 
disrupts protein folding and increases ubiquitination and degradation (16, 17). Other 
variants, such as F489L and N590Y have also been shown to affect BCRP expression 
and function, but are much less common and therefore are not as clinically relevant (18, 
19).   
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ABCG2 and Drug Development 
ABCG2 as a Target for Multi-Drug Resistance 
Once BCRP had been identified as a possible mechanism for the multi-drug resistance 
phenotype in cancer, many studies were performed to assess the impact of BCRP 
expression on clinical outcomes and chemotherapy treatment response.  Interestingly, 
expression of BCRP in breast cancer, the namesake of the protein, was found to be 
highly variable in clinical tumor samples and was not a significant predictor of prognosis 
or progression-free survival after treatment (20).  However in other cancers such as 
acute myeloid leukemia, non-small cell lung cancer, ovarian cancer, chronic myeloid 
leukemia and esophageal squamous cell carcinoma, tumor expression level of BCRP 
was found to have a significant association with survival and response to therapy with 
higher expression being linked to worse prognosis (21-24).  In a panel of 150 untreated 
solid tumors, BCRP expression was evident in all of them, but especially high in cancers 
of the digestive tract, endometrium, and lung, and in melanoma (25). These findings 
made BCRP a potential target for inhibition in chemotherapy-resistant cancers, 
especially for concomitant use with BCRP substrates (Figure 1.1).  
 
Although the identification of BCRP as a target in the treatment of cancer was exciting 
in principle, thus far BCRP inhibitors have fallen prey to the “valley of death” in drug 
development (26). Many potent and selective BCRP inhibitors have been identified via 
high-throughput screens and other methods, described in detail in other reviews(9, 27, 
28). Many of these inhibitors are able to re-sensitize multi-drug resistant cells to the 
cytotoxic effects of chemotherapeutics (9, 16). However, only a few BCRP inhibitors  
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Figure 1.1: Chemotherapies as BCRP substrates 
Thyroid:
Lenvatinib, Vandetanib,
 Sorafenib
Colon:
Irinotecan, Regorafenib
Ovary:
Doxorubicin, Niraparib,
Rucaparib, Topotecan, 
Oxaliplatin
Skin:
Dabrafenib, Vemurafenib
  Soft Tissue:
Pazopanib 
Breast:
Epirubicin, Lapatinib,
 Tamoxifen, Methotrexate,
Docetaxel, Palbociclib
Pancreas:
Erlotinib, Sunitinib,
 Mitomycin C
Liver:
Regorafenib
Stomach:
Imatinib, Sunitinib,
Mitomycin C
Blood:
Venetoclax, Bendamustine,
Idelalisib, Dasatinib, Imatinib,
Daunorubicin, Mitoxantrone,
Cladribine, Clofarabine, 
Mercaptopurine
Lymph:
Bendamustine, Idelalisib,
Methotrexate
Lung:
Ceritinib, Gefitinib,
Etoposide, Pemetrexed,
Topotecan,
Methotrexate,
Docetaxel, Afatinib,
Brigatinib, Osimertinib,
Erlotinib
Kidney:
Sunitinib, Lenvatinib,
Pazopanib, Sorafenib
Bladder:
Oxaliplatin
Testes/Prostate:
Oxaliplatin, Etoposide,
Bicalutamide, Docetaxel
Chemotherapeutics that have shown to be BCRP substrates are summarized 
by their approved indications. These compounds are at risk for multi-drug 
resistance and may benefit from the concomitant use of BCRP inhibitors in the 
clinic. Sources for each chemotherapy can be found in Table 1.1. Adapted and 
printed with permission from Designua/Shutterstock.com. 
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Table 1.1: References for Chemotherapies as BCRP Substrates 
References identifying each chemotherapy as a BCRP substrate. References 
are given as PubMed ID number or Package Insert (PI), accessed via the FDA 
archives before August 28, 2017 
 
Chemotherapy 
 
Reference 
(PMID) 
 Chemotherapy Reference 
(PMID) 
palbociclib 26123925  etoposide 12649196 
epirubicin 16619483  dabrafenib PI 
lapatinib PI  vemurafenib 23020847 
tamoxifen 12668685  afatinib PI 
methotrexate 14500392  brigatinib PI 
docetaxel 28327932  osimertinib PI 
venetoclax PI  erlotinib 18723475 
bendamustine PI  doxorubicin 10485464 
idelalisib PI  niraparib PI 
dasatinib 19491323  rucaparib 24962512 
irinotecan 10493507  pemetrexed 21628496 
imatinib 15251980  bicalutamide 25124867 
regorafenib 28479358  lenvatinib PI 
sunitinib 21309545  pazopanib  PI 
daunorubicin 11703319  sorafenib 20952483 
mitoxantrone 12153153  topotecan PI 
cladribine 17638908  pazopanib PI 
clofarabine 18765824  Mitomycin C 26305906 
mercaptopurine 18765824  oxaliplatin 18801423 
ceritinib 26361725  lenvatinib PI 
gefitinib 22548830  vandetanib 22633931 	
  10 
have made it to the clinic.  As of 2015, only 5 inhibitors had been evaluated in the clinic, 
usually in a phase I study. Multiple clinical trials investigated lapatanib and topotecan as 
a method for overcoming BCRP mediated drug-resistant cancers, but showed no 
clinical benefit in platinum-refractory/resistant ovarian/peritoneal cancer and had 
increased toxicities in HER2 positive breast cancer that led to the discontinuation of the 
trial (26, 29, 30). 
To further complicate clinical trials of BCRP inhibitors, a complex relationship was 
described between chemotherapies and BCRP regulation. Many studies found 
increased BCRP expression after treatment with chemotherapy, theoretically due to 
upregulation in the surviving tumor cells (31). The tyrosine kinase inhibitor gefitinib was 
found to decrease BCRP expression via inhibition of the EGFR pathway and re-
sensitize cells to SN-38, the active metabolite of irinotecan, when given in short term 
(32). After long-term exposure, however, the increased SN-38 levels reactivated EGFR 
and actually increased BCRP expression to again reduce the levels and cytotoxic 
effects of SN-38 (27). These in vitro studies complicate the use of TKIs as re-sensitizing 
agents in the clinic, where patients would have long-term exposure to both drugs. 
Further, the co-administration of topotecan and sulfasalazine was shown to induce 
BCRP expression by promoter demethylation, suggesting a number of different 
mechanisms by which cancer cells upregulate BCRP expression after exposure to 
chemotherapeutics (33).  
 
Thus, while reverse translational research led to the identification of BCRP as a target 
and even some early phase clinical trials, these trials have not resulted in an approved 
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therapeutic to improve efficacy of anti-cancer drugs.  A more complete understanding of 
the systems and proteins involved in the activity and regulation of BCRP may make the 
clinical administration of BCRP inhibitors as chemosensitizers more feasible.  Further, 
complete characterization of the binding sites and oligomerization of BCRP may offer 
even more insight into the development of more specific and less toxic inhibitors.  
 
Though the development of BCRP inhibitors has not been successful to date, some 
interesting studies have shown that BCRP expression can still serve as a marker of 
prognosis on treatment, even for drugs that are not substrates for the transporter. One 
study in acute myeloid leukemia showed that patients treated with cytarabine, which is 
not a substrate of BCRP, were much less likely to achieve complete remission if they 
had high BCRP expression. Two other studies confirmed these findings, showing 
associations between BCRP mRNA and either survival or complete response rate (34). 
Thus, expression of BCRP may be a biomarker for poor drug response irrespective of 
whether or not the chemotherapeutic agents are BCRP substrates. 
 
Statin Exposure 
The list of BCRP substrates is large and diverse. Because of its diverse substrate 
specificity and high expression in the intestine, kidney, and liver, BCRP plays an 
important role in the absorption, distribution, and excretion of many prescription drugs. 
While new drugs are now routinely screened as substrates/inhibitors of BCRP, this was 
not always the case, and thus, many older drugs including many statins are substrates 
of BCRP, and its variation in expression and activity can have a major impact on the 
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efficacy and safety of these medications.  In fact, there is perhaps no better example of 
the triumph and swift nature of reverse translational research than that of rosuvastatin 
and BCRP. While the average time to develop a drug is 10-12 years, the time it took to 
change the drug product insert based on observed ethnic differences in exposure to 
rosuvastatin was only two years (35). Perhaps more impressively, it would seem as 
though these observed ethnic differences could be almost entirely attributed to genetic 
polymorphisms in two membrane transporters: OATP1B1 (SLCO1B1) and BCRP.  
 
HMG-CoA reductase inhibitors, also known as statins, were introduced in 1987 with the 
development of lovastatin for lowering low-density lipoprotein cholesterol (LDL-C).  
HMG-CoA reductase catalyzes the rate-limiting step in the cholesterol biosynthetic 
pathway (36).  After lovastatin, synthetic statins such as atorvastatin and rosuvastatin 
were approved for the treatment of dyslipidemia (37). Rosuvastatin, marketed as 
Crestor, was approved by the FDA in August 2003 as the sixth statin on the market, 
with a maximum dose of 40 mg and a recommended starting dose of 10 mg daily for 
patients without renal impairment (38). Despite being the sixth statin on the market, 
Crestor is widely used and was the top statin on the market in 2015 according to 
revenue and sales (39).   
 
Clinical trials for the development of rosuvastatin were done primarily in subjects of 
European descent, and a dose-limiting muscle toxicity of myopathy and rhabdomyolysis 
was observed at a rate of 0.4 percent in subjects taking 80 mg daily (40). However, in 
an assessment of a multinational phase II/III program, no rhabdomyolysis was attributed 
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to rosuvastatin at doses <40 mg daily (41). Patients with conditions that increase 
exposure such as renal impairment or concomitant medications were found to have an 
increased risk of the dose-dependent toxicities of rosuvastatin (38, 40). When similar 
trials were performed in Japanese cohorts, a large increase in rosuvastatin exposure 
was observed compared to corresponding doses in Caucasian subjects (40, 42). This 
increase in exposure mixed with the exposure-dependent toxicities prompted 
AstraZeneca to release a revised drug insert suggesting a decreased starting dose for 
Asian subjects in March 2005, just two years after initial approval (38).  
 
Up to this time, the differences in exposure had only been observed in the clinic but 
could not be fully explained.  SLCO1B1 (OATP1B1) was known to take up rosuvastatin 
in the liver, and reduced-function variants had been previously associated with 
differences in other statin pharmacokinetics (43). However, many speculated that 
differences could also be attributed to diet and environmental factors. To best solve this 
problem, Lee, et al. studied rosuvastatin exposure in various ethnic groups all living 
within the metropolitan area of Singapore. They showed that Japanese subjects had up 
to twice the exposure as European subjects given the same dose, and that SLCO1B1 
genotypes could not account for the observed differences (44).  
 
This study provided strong evidence that there was a genetic factor causing the 
difference in exposure between the two ethnic groups, and encouraged further research 
into the mechanism. Unlike other statins, rosuvastatin did not undergo extensive 
metabolism and was excreted mostly as unchanged drug in the bile (37, 38). Among the 
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efflux transporters that could potentially be determinants of rosuvastatin exposure, 
BCRP, MDR1, or MRP2, BCRP indeed transported rosuvastatin (45). Thus, further 
studies were done to determine the effect of BCRP genetic polymorphisms on 
rosuvastatin exposure. One study, in healthy Chinese males, showed that when 
controlling for CYP2C9 and SLCO1B1 variation, BCRP Q141K significantly increased 
the AUC and decreased the CL/F for rosuvastatin (46). Another study in healthy Finnish 
volunteers showed that even in European subjects, the Q141K polymorphism markedly 
affected rosuvastatin exposure (47). Recent studies have suggested that when 
controlling for both ABCG2 and SLCO1B1 genotype, the difference in rosuvastatin 
exposure between Asian and Caucasian volunteers is nullified, although the study was 
not powered to detect modest differences. Previous studies have shown that with larger 
sample sizes, there are still intrinsic ethnic differences between the two population’s 
rosuvastatin pharmacokinetics that are not explained by BCRP and SLCO1B1 variants 
(48, 49). 
 
Though the FDA and other regulatory bodies do not require BCRP genotyping before 
dosing rosuvastatin, and the product label suggests giving a lower dose to individuals of 
East Asian ancestry, the data point to genotypes being the driving safety concern for 
dosing rather than ethnicity.  Many individuals of non-East Asian ancestries harbor the 
BCRP Q141K variant, and these individuals should potentially be started on lower 
doses. Further, East Asians without the BCRP Q141K variant or reduced OATP1B1 
function may benefit from higher doses, although larger studies are still needed to verify 
this benefit.   Clearly, studies of the BCRP polymorphism and its effect on rosuvastatin 
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exposure and adverse drug reactions have underscored the importance of BCRP in 
drug disposition, especially for drugs with narrow therapeutic indices. Due to the high 
prescription rate of statins and their potential for rare, but life-threatening adverse 
effects, the FDA now recommends screening new molecular entities for their inhibition 
or transport by BCRP to avoid drug-drug interactions. The International Transporter 
Consortium has issued recommendations for the design and implementation of these 
drug-drug interaction studies, and suggests a pharmacogenetic approach to any new 
molecular entity in which BCRP plays a large role in the disposition or response due to 
the high allele frequencies of the reduced function BCRP Q141K variant (50, 51), 
especially considering the number of BCRP substrates on the World Health 
Organization list of essential medicines (Figure 1.2).   The change in regulatory 
guidance for BCRP represents a true outcome of reverse translational research focused 
on BCRP.  Beginning with the observation that Asians have increased exposure and 
consequently more adverse events, the mechanisms were then identified and related to 
genetic polymorphisms in ABCG2. Dosing recommendations were changed for Asians, 
and extrapolated to guidances focused on BCRP-mediated drug-drug interactions, 
which can phenocopy the effects of genetic polymorphisms.  
 
Sunitinib and Irinotecan Toxicities 
While pre-emptive screening helps identify BCRP-mediated drug-drug interactions that 
can lead to issues with safety and efficacy, a number of drugs that were approved 
before the discovery of BCRP have toxicities that have been since attributed to variation 
in BCRP activity and expression.  Irinotecan, used for the treatment of colorectal and  
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Figure 1.2: ABCG2 c.421C>A (BCRP Q141K) Allele Frequencies 
BCRP (Reference)
BCRP Q141K
WHO List of Essential Medicines: Interactions with BCRP
Abacavir*
Aciclovir
Albendazole
Allopurinol
Amlodipine
Atazanavir
Beclomethasone
Benzylpenicillin
Budesonide
Cefazolin
Ceftriaxone
Chloroquine
Chlorpromazine
Ciprofloxacin*
Clofazimine
Clopidogrel
Efavirenz
Ergometrine
Folic Acid
Lopinavir
Mefloquine
Nifurtimox
Nitrofurantoin*
Ondansetron
Proguanil
Quinine
Riboflavin*
Risperidone
Ritonavir
Saquinavir
Simeprevir
Tenofovir
Warfarin*
Zidovudine
The allele frequencies for the reduced-function ABCG2 c.421C>A (BCRP 
Q141K) variant are shown for world populations (actual percentages in Table 
1.2). This variant is common among Hispanic, Asian, and Caucasian 
populations and could cause complications in the administration of BCRP 
substrates and inhibitors, which are numerous. For example, there are 42 
compounds that interact with BCRP on the World Health Organization List of 
Essential Medicines, listed here. An asterisk (*) indicates substrates for which 
BCRP activity has been shown to significantly affect pharmacokinetics in vivo. 
Sources for each medication can be found in Table 1.3.  
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Continent Population Location Ref c.421C>A 
Africa ACB Barbados 0.990 0.010 
Africa ESN Nigeria 1.000 0.000 
Africa GWD The Gambia 0.987 0.013 
Africa LWK Kenya 1.000 0.000 
Africa MSL Sierra Leone 0.982 0.018 
Africa YRI Nigeria 1.000 0.000 
Asia CDX,CHB,CHS China 0.739 0.261 
Asia JPT Japan 0.678 0.322 
Asia KHV Vietnam 0.657 0.343 
Asia BEB Bengladesh 0.878 0.122 
Asia PJL Pakistan 0.896 0.104 
Europe FIN Finland 0.909 0.091 
Europe GBR England, Scotland 0.857 0.143 
Europe IBS Spain 0.930 0.070 
Europe TSI Italy 0.939 0.061 
N. America MXL Mexico 0.797 0.203 
N. America PUR Puerto Rico 0.894 0.106 
S. America CLM Colombia 0.867 0.133 
S. America PEL Peru 0.853 0.147 	
Table 1.2: Allele Frequencies of ABCG2 c.421C>A by Sub-Population 
Allele frequencies of reference ABCG2 and ABCG2 c.421C>A for the 
subpopulations described in Figure 1.2 (15). 
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Medication PMID Medication PMID 
Abacavir 17437964, 
28696229, 
18443033 
Lopinavir 20551216 	
Aciclovir 21859328 Mefloquine 25218605 	
Albendazole 18523872 Nifurtimox 22200378 	
Allopurinol 25676789 Nitrofurantion 22004608, 
20607366 
	
Amlopidine 22200670 Ondansetron 26584727 	
Atazanavir 20551216 Proguanil 25218605 	
Beclomethasone 15365089 Quinine 25218605 	
Benzylpenicillin 27300692 Riboflavin 17145775 	
Budesonide 16442095 Risperidone 18834354 	
Cefazolin 18339814 Ritonavir 15007102 	
Ceftriaxone 18339814 Saquinavir 17202245 	
Chloroquinine 25218605 Simeprevir 26353895 	
Chlorpromazine 18834354 Tenofovir 24413260 	
Ciprofloxacin 16434544, 
17639028 
Warfarin 28093289 	
Clofazimine 26682943 Zidovudine 17437964 	
Clopidogrel 26700956   
Efavirenz 21803024   
Ergometrine 22147614   
Folic Acid 28300564   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    	
Table 1.3: PubMed ID Numbers for BCRP Substrates or Inhibitors on the 
WHO List of Essential Medications 
PubMed ID numbers identifying WHO essential medications as a BCRP 
substrate or inhibitor. Additional PubMed ID numbers are given for 
medications with evidence of change in pharmacokinetics in knockout 
models or clinical studies.  
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lung cancers, was identified as a BCRP substrate; that is, high BCRP expression in 
tumors associated with non-response to the drug (52). However, a number of patients 
also experienced myelosuppression and early-onset diarrhea, dose-limiting toxicities of 
the drug.  These toxicities were associated with high steady-state concentrations of 
irinotecan and its active metabolite, SN-38 (53). One study, screening 170 SNPs in 14  
candidate genes, showed that rs2622604, a SNP in the first intron of ABCG2 correlated 
significantly with severe myelosuppression in patients taking irinotecan (54). Because 
this SNP is intronic, its relation to irinotecan pharmacokinetics is unknown, but these 
results suggest that the SNP may increase irinotecan exposure, perhaps by 
modification of BCRP expression or activity.  
 
Similar studies were conducted for other substrates of ABCG2 with dose-limiting 
toxicities, such as sunitinib and gefitinib.  Sunitinib, a tyrosine kinase inhibitor known to 
interact with BCRP, has a number of toxicities including thrombocytopenia, leukopenia, 
mucosal inflammation, and hand-foot syndrome (55).  Risk for any of these toxicities at 
a grade of 2 or higher was significantly increased by reduced function BCRP variants, 
and specifically the BCRP Q141K variant was linked to an increased risk for grade 3 or 
4 thrombocytopenia even after correcting for non-genetic risk factors.  This could be due 
to higher exposure, as one group attributed an increased AUC of sunitinib to the BCRP 
Q141K variant and replicated these findings in Abcg2(-/-) mice (55, 56). Inclusion of 
BCRP Q141K in the population PK model for sunitinib was found to significantly 
improve the estimation of clearance (57).   
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BCRP Q141K was also linked to an increased risk for developing grade 1 or 2 diarrhea 
following gefitinib treatment in non-small cell lung cancer (58). These findings exemplify 
the importance of pharmacogenetic studies for BCRP substrates for more precise 
dosing of drugs with narrow therapeutic indices or dose-limiting toxicities. Though 
currently, there are no expert guidelines for use of BCRP genotype information in 
clinical dosing, such as a Clinical Pharmacogenetics Implementation Consortium paper, 
continued research and validation of the association of BCRP variants with toxicities to 
anti-cancer agents, may eventually result in clinical guidelines and genotype-driven 
dosing of various drugs.    
 
The Endogenous Role of ABCG2 
Due to its high levels of expression in tissues vital to the absorption, distribution, and 
excretion of exogenous compounds, BCRP functions as a barrier between vital organs 
and toxic compounds. This is especially true in some of the body’s most sensitive 
tissues, the placenta and brain. BCRP is highly expressed in the Blood-Brain Barrier 
(BBB), and has been shown to protect the brain from toxic pharmaceuticals as well as 
endogenous compounds such as porphyrins that can be toxic at high levels and under 
hypoxic conditions (59).  
 
Some of the endogenous roles and regulation of BCRP have been uncovered via in 
vitro studies and studies in knockout mice, which have then been translated to the clinic. 
Large, high-throughput screens offer a quick way to screen compounds for their ability 
to inhibit BCRP, but these screens tend to generate a number of false positives. 
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Further, these large-scale screens give no information about the importance of a 
compound’s disposition in vivo. As a prime example, almost all of the statins are 
substrates for the transporter, but only rosuvastatin and atorvastatin exposure seem to 
be altered by BCRP genotype, likely due to intrinsic differences in intestinal 
bioavailability and the contribution of BCRP to both the absorption and excretion of each 
statin (60).  
 
Though translational studies from mice to humans have revealed much about the 
pharmacological role of BCRP, genome-wide association studies (GWAS) in the 
reverse translational direction, have revealed the endogenous roles of BCRP, and in 
particular, its role in uric acid disposition. 
 
Uric Acid Levels and Gout 
Gout is a painful arthritic disease that manifests as uric acid crystals in the joints of the 
body. Hyperuricemia or high uric acid levels in the serum (>6.8 mg/dL) is the central risk 
factor for developing gout, which has been associated with fatal comorbidities such as 
chronic kidney disease, stroke, and myocardial infarctions (61). In 2008, the first 
genome-wide association study (GWAS) on uric acid levels and dyslipidemia was 
performed, identifying genetic variants in SLC2A9 as a risk for high uric acid levels. 
Replication cohorts and further studies expanded on these findings, and with increasing 
numbers, an association between ABCG2 variants and uric acid levels was uncovered 
(62). Specifically, the BCRP Q141K variant was linked to high uric acid levels.  
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These GWAS led to the hypothesis that BCRP was a uric acid transporter and played a 
role in uric acid handling in the kidney and/or intestine, a function that was not 
previously known. Indeed, in vitro studies confirmed that BCRP is a high capacity uric 
acid transporter with a Km and Vmax of 8.24 ± 1.44 mM and 6.96 ± 0.89 nmol/min/mg 
protein, respectively (63). Many elegant studies following the initial GWAS have 
identified BCRP as not only an important factor in the kidney “urate transportersome” 
but also as a vital transporter for uric acid excretion in the intestine (64).   
 
Since then, researchers have categorized gout and hyperuricemia into two clinical 
subtypes: renal under-excretion and renal overload.  Renal under-excretion results from 
reduced excretion of urate in the kidney, potentially due to kidney disease or genetic 
polymorphisms in renal urate transporters. Renal overload, on the other hand, results 
from reduced extra-renal excretion or overproduction of uric acid (64, 65). Both 
subtypes have been linked to BCRP dysfunction, but recent studies in chronic kidney 
disease patients suggest that BCRP may be the most important factor for extra-renal 
excretion of uric acid, as it is the top gene that associates with uric acid levels in 
patients with deteriorated kidney function (66).  
 
This distinction, stemming from a better understanding of the underlying mechanisms in 
urate handling, has generated many hypotheses on more precise treatment for 
hyperuricemia and gout. One GWAS in particular found that splitting subjects by their 
clinical subtype of gout revealed unique associations between genetic risk factors and 
clinical parameters such as fractional excretion of uric acid and urinary urate excretion, 
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suggesting that these genes play different roles depending on the clinical manifestation 
of gout (67). Future studies are needed to determine the most effective treatment for 
each clinical subtype.  
 
ABCG2 variation has also proven to be a useful probe in deciphering the relationship 
between uric acid levels and other risk factors for comorbidities. Uric acid levels have 
been shown to associate with comorbidities of gout such as cardiovascular disease, 
type 2 diabetes, and chronic kidney disease. However, the cause and effect relationship 
between these disease states is largely unknown. The genetic architecture of urate 
levels and gout has been used to create a genetic urate score that can be used to 
predict uric acid levels and risk for gout. These factors were not good predictors for 
cardiovascular disease or chronic kidney disease, suggesting that uric acid levels may 
not be the sole determinant of these conditions (68).  
 
Recently, ABCG2 has also been implicated in response to the gout treatment allopurinol 
through GWAS. Allopurinol is a xanthine oxidase inhibitor and closely resembles uric 
acid and its precursor, xanthine.  A GWAS in 2,027 multi-ethnic subjects linked the 
BCRP Q141K variant with a reduced response to allopurinol, with an independent study 
replicating these results, confirming adherence to the drug by accounting for plasma 
drug levels in subjects (69, 70). Further studies are needed to confirm the role of BCRP 
variation on the pharmacokinetics and pharmacodynamics of allopurinol and other 
xanthine oxidase inhibitors.  
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Other Genome-Wide Association Studies 
Through GWAS, genetic variants in ABCG2 have been associated with a number of 
other phenotypes highlighted in Table 1.4. The wide array of BCRP substrates and high 
allele frequencies of reduced-function variants make it easier to detect BCRP-related 
changes in endogenous and exogenous substrate levels through GWAS. Beyond its 
associations with gout, uric acid levels, allopurinol response and LDL cholesterol 
lowering in patients taking statins, BCRP has also been associated at suggestive p-
values with caffeine intake, sitting height ratio, Lipoprotein-associated phospholipase 
A(2) change, and dental caries. Many of these findings still require replication and 
functional studies to determine the mechanism by which BCRP variation plays a role, 
but offer further opportunities for reverse translational research (71). 
 
Alzheimer’s Disease and Amyloid Beta Deposition 
GWAS represent a useful tool for probing how genetic variation can impact a 
phenotype, but gene expression studies are an even more direct method of determining 
the role of protein expression in metabolite levels and disease risk. The link between 
BCRP and Alzheimer’s Disease (AD) was discovered via gene expression screening in 
human brain tissue, and has since been explored as a potential biomarker of the 
devastating disease.  
 
The prevalence of AD, the most common form of dementia, is on the rise. An estimated 
24 million people suffer from this disease globally, with approximately 95% of those 
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Phenotype Subjects Ethnicities PMID 
Allopurinol Response: SUA 1,492 Caucasian 25676789 
Gout 22,871 Caucasian 18834626 
Gout 28,283 Caucasian 20884846 
Gout 40,968 Icelanders 21983786 
Gout 69,374 Caucasians 23263486 
Gout* 19,427 Multi-Ethnic 23552988 
Gout 4,540 Japanese 25646370 
Gout 4,822 Japanese 27899376 
Gout 10,902 Caucasian 19506252 
Gout 3,103 Han Chinese 28642574 
Rosuvastatin Response: Lp-PLA2 2,673 Caucasians 23118302 
ROL gout* 1,709 Japanese 25646370 
ROL gout 3,659 Japanese 27899376 
RUE gout* 1,843 Japanese 25646370 
RUE gout 3,796 Japanese 27899376 
Statin Response: Absolute LDL-C 6,989 Caucasians 22331829 
Statin Response: Fractional LDL-C 6,989 Caucasians 22331829 
SUA 22,871 Caucasian 18834626 
SUA 28,141 Caucasian 19503597 
SUA 8,868 Japanese 20139978 
SUA 28,283 Caucasian 20884846 
SUA 15,506 Icelanders 21983786 
SUA 110,347 Caucasians 23263486 
SUA* 39,853 Multi-Ethnic 23552988 
SUA 12,281 Chinese 24513273 
SUA 5,911 Indian 26902266 
SUA 33,074 East Asians 22797727 
SUA (lean subjects) 14,504 Caucasian 25811787 
SUA (overweight subjects) 17,078 Caucasian 25811787 	
Table 1.5: References for Genome-Wide Associations with ABCG2 Variants 
PubMed ID numbers for each study described in Table 1.4. 
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cases being late onset. In comparison to early onset disease, which can be attributed to 
highly penetrant variants in genes for Amyloid Precursor Protein (APP) breakdown such 
as APOE and amyloid-beta (A-beta) generation, the genes responsible for late-onset 
AD are much more complex and therefore still being investigated (72).  
 
AD is characterized by A-beta peptides deposited extracellularly in diffuse and neuritic 
plaques. However, the mechanism by which these A-beta peptides cross the BBB was 
unknown until 2009. Using gene expression analysis in brains from AD patients as well 
as Abcg2 null mice, Xiong, et al found that BCRP played an important role in preventing 
the deposition of these peptides in the brain (73).   In particular, BCRP expression was 
upregulated in brain tissue from AD patients. Conversely, Abcg2 null mice showed an 
increased accumulation of labeled A-beta peptides compared to wild-type mice as well 
as an increase in NF-KB activation. Cell studies showed that A-beta peptide activated 
microglia could actually stimulate the expression of BCRP, further supporting the idea 
that BCRP protects the brain from A-beta peptides through efflux mechanisms (73, 74). 
Some studies have failed to replicate the original upregulation of BCRP in AD brains, 
although this may be attributed to which regions of the brain are studied (74).  
 
Because of its proposed role in A-beta peptide deposition, BCRP Q141K was 
investigated for an association with Alzheimer’s risk.  Although it does associate with a 
small increase in risk, this association is most pronounced in those carrying the APOE4 
risk variant (75). However, replication and validation are still necessary.  
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Summary and Conclusions 
BCRP was originally discovered via reverse translational research as a possible 
mechanism for multi-drug resistance in cancer treatment because of its efficient efflux of 
a number of chemotherapeutics. Since then, it has been described as a broad-spectrum 
efflux transporter that regulates circulating levels of its substrates, both xenobiotic 
compounds and endogenous metabolites. Reduced-function variants in ABCG2, 
specifically BCRP Q141K, have been associated with changes in pharmacokinetics and 
pharmacodynamics of drugs that have resulted in reduced efficacy and increased 
toxicities in patients carrying these variants. Rosuvastatin is perhaps the most widely 
used and well known of these drugs, and differences in PK/PD were originally attributed 
to ethnic differences. Since then, reverse translational research has shown that genetic 
variation in SLCO1B1 and ABCG2 in both Asian and Caucasian patients contribute to 
the large variation in drug exposure and response, regardless of ethnicity.  
 
Of the many endogenous metabolites of BCRP, uric acid has garnered quite a bit of 
interest in the field because of its discovery via GWAS. Genetic variants in ABCG2 
associated with SUA levels in various ethnic groups, and further functional studies 
confirmed that BCRP and its reduced-function variants play a role in uric acid 
homeostasis and risk for gout and hyperuricemia. These variants, due to their strong 
predictive value, have since been used as probes for testing the associations between 
uric acid levels and comorbidities of high uric acid as well as discerning between clinical 
subtypes of gout.  While uric acid is the major success story of discovering BCRP’s 
endogenous role, ABCG2 variants have been associated with other phenotypes in 
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GWAS including response to the anti-gout medication, allopurinol.  These studies 
suggest the potential for future reverse translational studies to further elucidate the role 
of BCRP in the disposition of other drugs, beyond statins, methotrexate and allopurinol, 
which are substrates of the transporter.    
 
BCRP’s endogenous role has also been identified via gene expression studies, 
regardless of genotypic variation. Expression levels in brain tissues with Alzheimer’s 
disease identified the upregulation of BCRP as a potential protective function from the 
disease. These studies showed that a build up of A-beta peptides could stimulate the 
upregulation of the transporter to protect precious brain tissue from the harmful peptide. 
Further studies will be needed to identify whether BCRP upregulation could be a 
druggable target for the prevention of Alzheimer’s Disease.  
 
Reverse translational research improves upon translational research by incorporating 
observed clinical data into preclinical models that not only validate these models but 
characterize the mechanisms behind the observed clinical phenotype. Here we have 
described a number of tools and studies that have successfully determined the role of 
BCRP as a drug target, modulator of pharmacokinetics and pharmacodynamics, and 
mediator of endogenous metabolite levels. This efflux transporter is of particular 
importance in drug development because of its role in drug disposition and drug-drug 
interactions, but recently has also been shown to be important in the pathogenesis of 
disease states. Great focus should be placed on elucidating the complex regulation and 
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endogenous role of BCRP to better understand the dosing of its substrates as well as 
the potential of drugging it as a therapeutic target.  
 
Statement of Purpose 
In this dissertation, we use a reverse translational research approach to identify genetic 
determinants of allopurinol response, the first-line treatment for chronic gout. Although 
much has been done in discovering genetic mechanisms for the development of gout, 
little is known about the pharmacogenetic determinants in its treatment. Thus, we 
performed two major studies, presented in two chapters.  In chapter 2, we present our 
findings from the largest GWAS conducted so far on allopurinol response in multi-ethnic 
cohorts and independent replication cohorts to identify the genetic determinants of 
allopurinol response. We then use in vitro cell uptake studies to further understand 
these associations. Chapter 3 provides an in-depth characterization of the relationship 
between the genetic variant of BCRP, BCRP Q141K, and allopurinol response, using a 
clinical study in healthy volunteers to describe the impact of genetics on allopurinol 
pharmacokinetics and pharmacodynamics. Taken together, these studies can be used 
to determine the best strategy for applying these findings back into the clinic for more 
effective treatment of gout. 
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Chapter 2: Genome-wide Association and Functional Studies Reveal Novel 
Pharmacological Mechanisms for Allopurinol 
 
Introduction 
Gout is an inflammatory arthritis caused by the deposition of uric acid as crystals in the 
synovial fluid of the joints. These attacks are typically caused by chronically high levels 
of serum uric acid (SUA), or hyperuricemia, and are characterized by the extreme pain 
and discomfort they cause for patients. A number of environmental risk factors for gout 
including purine-rich diet and alcohol consumption have led to a consistent rise in its 
prevalence over the past few decades (1). The painful and debilitating attacks 
associated with this disease as well as the underlying hyperuricemia have been shown 
to be risk factors for various diseases including coronary heart disease, stroke, and 
chronic kidney disease (2-5).  Thus, management of gout and hyperuricemia has 
become increasingly important in the prevention of life-threatening cardiac and renal 
diseases.  
 
Currently, allopurinol is the first-line treatment for chronic gout. The major mechanism of 
action of allopurinol is reduction in uric acid synthesis through inhibition of xanthine 
oxidase, the major enzyme for the production of uric acid (6). Response to allopurinol is 
highly variable, with as few as 21% of subjects maintaining the rheumatologist 
recommended SUA levels of <6 mg/dL for three consecutive months in a prospective 
clinical trial (7). While poor adherence is a commonly cited problem for allopurinol, 
inadequate dosing as well as inter-individual differences in pharmacokinetics or 
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pharmacodynamics are also major factors for suboptimal response. This leaves a large 
number of hyperuricemic patients at an increased risk for developing life-threatening 
comorbidities, even those that are adherent to treatment (8).  
 
To identify factors involved in the response to allopurinol, our laboratory previously 
performed a genome-wide association study (GWAS) on allopurinol-induced change in 
SUA. Using a multiethnic cohort of 2,027 subjects taking allopurinol, we identified 
genetic variants in ABCG2, which encodes the efflux transporter Breast Cancer 
Resistance Protein (BCRP), as determinants of allopurinol response, and showed that 
oxypurinol, the active metabolite of allopurinol and more efficacious inhibitor of xanthine 
oxidase, is a substrate of BCRP. While one noncoding region variant in ABCG2, 
rs10011796, associated with poor response to allopurinol at a genome-wide level of 
significance, several observations about the role of ABCG2 in allopurinol response were 
puzzling.  First, though the common missense variant of ABCG2, BCRP Q141K 
(rs2231142), associated with worse response, the association was not significant at a 
genome-wide level (9).  Second, the direction of the association was contradictory to the 
expected interaction between allopurinol levels and BCRP function. That is, the reduced 
function variant associated with worse response to allopurinol after correcting for other 
factors that affect allopurinol response such as baseline, dose, and concomitant 
medications.  A reduced function variant in a renal (or intestinal) secretory transporter 
for allopurinol may be expected to be associated with higher systemic levels of 
oxypurinol and allopurinol, therefore, better response to the drug, yet that is not the 
association we observed.  These enigmatic observations led us to our current study.  
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Here, we aimed to discover novel genetic determinants of allopurinol response and 
provide evidence to support our previous observations. Specifically, we considered the 
following questions: (1) Does BCRP Q141K associate with worse response to 
allopurinol at genome-wide significance? (2) Does this variant appear to be the causal 
variant for the association? (3) What mechanisms can explain the association of a 
reduced function variant in ABCG2 with poor response to allopurinol?  To address these 
questions, we expanded our previous cohort to perform the largest GWAS on allopurinol 
response to date. In addition to the expanded cohort, we analyzed two independent 
cohorts to validate our top associated loci. Finally, we performed in vitro studies to 
unravel the mechanisms responsible for the association between BCRP Q141K and 
poor response to allopurinol.  
 
Results 
The basic characteristics of the study populations are described in Table 2.1, and more 
detail is provided in the Methods section.  In brief, samples from a total of 3,517 
subjects on allopurinol were gathered for genome-wide analysis and samples from a 
total of 4,446 subjects on allopurinol were used for validation and replication. ALLO1 
and ALLO2 represent cohorts from the same clinical site and only differ in the time that 
their DNA was genotyped. ALLO1 was genotyped as a part of a larger cohort, the 
Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort (10). ALLO1  
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Table 2.1: Study Cohorts  
Four cohorts were gathered for analysis. ALLO1 and ALLO2 represent multiethnic 
cohorts from the Kaiser Permanente Research Program on Genes Environment 
and Health (RPGEH) and were genotyped on genome-wide platforms. They differ 
only in their genotyping platform and the time of data gathering. MARSH and 
BioVU were gathered as replication cohorts from Marshfield Clinic and Vanderbilt 
University Medical Center, respectively, and genotyped for top loci. 
eGFR, estimated glomerular fitration rate; SUA, serum uric acid 
*eGFR was calculated from serum creatinine levels using CKD-EPI equation 
Subjects 2,769 748 328 601
Genotyping Genome-wide Genome-wide ABCG2 ABCG2, GREM2
Males 74.4 73 65.9 63.7
Females 25.6 27 34.1 36.3
Non-Hispanic Whites 78.3 87.2 97.0 83.5
East Asians 12.1 6.4 0.3 1.8
African Americans 4.4 2.7 0.3 11.8
Latinos 4.5 2 0.6 0
Other 0.7 1.7 1.2 2.8
Age at Treatment 69.1 (61.6, 76.4) 69.3 (63.7, 75.6) 69.0 (57.3, 77.3) 58 (43, 68)
Baseline SUA (mg/dL) 9.1 (8.0, 10.2) 9.1 (8.0, 10.2) 8.1 (7.1, 9.5) 7.1 (5.1, 9.0)
Post SUA (mg/dL) 6.4 (5.4, 7.7) 6.4 (5.4, 7.6) 5.9 (5.0, 7.2) 5.4 (3.7, 7.1)
SUA Change (mg/dL) -2.5 (-3.8, -1.2) -2.6 (-3.7, -1.3) -2.1 (-3.1, -1.0) -1.6 (-3.0, -0.4) 
Allopurinol Dose (mg/day) 200 (100, 300) 200 (100, 300) 300 (100, 300) 300 (100, 300)
Nonadherent Days (percent) 0 (0, 0) 0 (0,0) NA NA
eGFR* at Treatment 58.9 (44.2, 74.0) 57.8 (45.4, 72.8) NA NA
ALLO1 ALLO2 MARSH BioVU
Percent
Median (Interquartile Range)
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contains the cohort analyzed in Wen et al (9), although since that analysis has been 
completed more subjects that had already been genotyped met inclusion criteria, due to 
longitudinal follow up that was recorded in updated electronic health record (EHR) data, 
and have been included in this analysis.  Samples from qualified subjects in BioVU (11) 
and MARSH (12) were gathered and genotyped as independent replication cohorts. The 
major phenotype assessed in this study was initial uricemic response to allopurinol, 
which was defined as the change in SUA (treated-untreated) at the first follow-up 
appointment. Untreated SUA levels were defined as any SUA level within 1.5 years of 
starting allopurinol treatment. Treated SUA levels were recorded at least 4 days after 
starting allopurinol and no more than 7 days after stopping allopurinol. A single 
treatment period was used for each subject, to avoid confounding by non-adherence 
and dose changes.  
 
Using change in SUA from baseline as the primary phenotype, we performed a GWAS 
in ALLO1 and ALLO2 in each separate ethnic group, and combined results using 
inverse-variance weighted meta-analysis (Figure 2.1). Any ethnic group with less than 
50 people was not included for analysis because of overfitting. In the largest ethnic 
cohort, the Non-Hispanic White population, the top SNP associated with worse 
response to allopurinol (rs45499402, C allele beta= 0.323 ± 0.055, p=4.53 x 10-9). This 
SNP is found in the ABCG2 locus and is in perfect linkage disequilibrium (LD, r2=1 (13)) 
with rs2231142 (Table 2.2, beta=0.323 ± 0.055, p=4.74 x 10-9), which encodes a 
glutamine to lysine change in the efflux transporter BCRP (BCRP Q141K) that reduces 
cell membrane expression, thereby reducing transport function. The trans-ethnic meta-
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analysis showed a strong association with this same missense variant (Table 2.3, beta= 
0.29 ± 0.05, p= 5.36 x 10-9). Conditional analysis in the Non-Hispanic White cohort, 
which included rs2231142 genotype as a covariate, reduced the p-value of the next 
strongest association within the ABCG2 locus to p=0.03, suggesting that either BCRP 
Q141K or a SNP in high LD is the causal SNP for the association with worse response 
to allopurinol (Table 2.4). This means that given the same dose and similar 
characteristics, subjects with the BCRP Q141K variant have on average 0.3 mg/dL less 
change in SUA on allopurinol. SNPs in the intronic region of GREM2, a secreted 
antagonist of the bone monomorphic protein (BMP), associated with better response to 
allopurinol with suggestive significance (rs77567654, G allele beta=-0.232 ± 0.04, p= 
1.40 x 10-7). This SNP is in strong LD (r2=0.71) with rs1934341, also in the intron of 
GREM2, which is the top associated genotyped variant within this region (Table 2.3, 
beta=-0.216 ± 0.04, p= 4.03 x 10-7).  
 
Because variants in ABCG2 were previously identified as determinants of allopurinol 
response, we gathered two independent replication cohorts and genotyped them for 
ABCG2 variants identified in our analysis. The association with the reduced function 
BCRP Q141K was strengthened with the addition of these replication cohorts (Figure 
2.2, beta=0.293 ± 0.05, p=8.06 x 10-11) strongly supporting a role for the efflux 
transporter in allopurinol’s uric acid lowering effects. We gathered genotypic data from 
355 BioVU subjects to replicate our suggestive association with variants in GREM2. In 
fact, rs1934341 associated with improved response in all of our cohorts as well as  
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Figure 2.1: Manhattan Plots of Allopurinol Response GWAS  
Manhattan plot of associations with change in serum uric acid following 
allopurinol initiation in (A) 2,647 Non-Hispanic White subjects and (B) trans-
ethnic meta-analysis including 2,647 Non-Hispanic Whites, 303 Asians, 115 
African-Americans and 114 Latinos. Genome-wide significance (5 x 10-8) and 
suggestive significance (5 x 10-6) have been marked. P-values < 0.05 are not 
graphed. 
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SNP	 CHR	 BETA	 SE	 P	 GENE	 TYPE	 A1	
rs2231142	 4	 0.323	 0.055	 4.74	x	10-9	 ABCG2	 missense	 T	
rs4148155	 4	 0.321	 0.055	 7.94	x	10-8	 ABCG2	 intron	 G	
rs57449396	 3	 0.606	 0.12	 4.80	x	10-7	 TBL1XR1,NAALADL2	 intergenic	 T	
rs10802887	 1	 -0.222	 0.046	 1.24	x	10-6	 GREM2	 intron	 G	
rs4148157	 4	 0.290	 0.061	 2.20	x	10-6	 ABCG2	 intron	 A	
rs61816456	 1	 -0.226	 0.048	 3.31	x	10-6	 NTNG1,	AMY1A	 intergenic	 A	
rs79663562	 2	 0.446	 0.096	 3.55	x	10-6	 MYT1L	 intron	 C	
rs1934341	 1	 -0.212	 0.046	 5.04	x	10-6	 GREM2	 intron	 T	
rs10011796	 4	 0.188	 0.041	 5.06	x	10-6	 ABCG2	 intron	 T	
rs2725215	 4	 0.288	 0.063	 5.71	x	10-6	 PKD2	 intron	 T		
Table 2.2: Top SNPs Associated with Allopurinol Response in Non-Hispanic 
White Cohort 
 
Top associations from the genome-wide association studies in 2,647 Non-
Hispanic Whites. To avoid reporting multiple SNPs in linkage disequilibrium, 
imputed data was filtered based on SNPs on the Affymetrix Axiom World 
genotyping platform and top 10 SNPs are shown. A1 represents the allele that the 
effect size is based on. Effect is defined as change in SUA (treated-untreated), 
therefore positive betas represent worse response to allopurinol.   
 
Abbreviations: SNP, Single Nucleotide Polymorphism; CHR, Chromosome; SE, standard error 
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SNP	 CHR	 BETA	 SE	 P	 GENE	 TYPE	 A1	
rs2231142	 4	 0.290	 0.050	 5.36	x	10-9	 ABCG2	 missense	 T	
rs4148155	 4	 0.289	 0.050	 7.89	x	10-9	 ABCG2	 intron	 G	
rs1934341	 1	 -0.216	 0.043	 4.03	x	10-7	 GREM2	 intron	 T	
rs10802887	 1	 -0.207	 0.042	 7.17	x	10-7	 GREM2	 intron	 G	
rs10011796	 4	 0.191	 0.039	 7.45	x	10-7	 ABCG2	 intron	 T	
rs4148157	 4	 0.257	 0.054	 2.31	x	10-6	 ABCG2	 intron	 A	
rs10193126	 2	 -0.183	 0.039	 3.23	x	10-6	 TRIB2,	FAM84A	 intergenic	 C	
rs9366772	 6	 -0.265	 0.057	 3.47	x	10-6	 HLA-C,	HCG27	 intergenic	 A	
rs76979899	 4	 0.249	 0.055	 4.92	x	10-6	 ABCG2	 intron	 T	
rs4659982	 1	 -0.179	 0.039	 5.82	x	10-6	 GREM2	 intron	 C		
Table 2.3: Top SNPs Associated with Allopurinol Response in Trans-Ethnic Meta-
Analysis  
Top associations from the genome-wide association studies in trans-ethnic meta-
analysis including 2,647 Non-Hispanic Whites, 303 Asians, 115 African-
Americans and 114 Latinos. To avoid reporting multiple SNPs in linkage 
disequilibrium, imputed data was filtered based on SNPs on the Affymetrix Axiom 
World genotyping platform and top 10 SNPs are shown. A1 represents the allele 
that the effect size is based on. Effect is defined as change in SUA (treated-
untreated), therefore positive betas represent worse response to allopurinol.  
 
Abbreviations: SNP, Single Nucleotide Polymorphism; CHR, Chromosome; SE, standard error 
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SNP BETA SE P A1 
rs114753515 0.326 0.15 0.032 T 
rs1466480 -0.154 0.075 0.040 A 
rs79565967 -0.296 0.17 0.075 T 
rs113506120 -0.165 0.099 0.095 C 
rs45570646 -0.298 0.18  0.099 C 	
Table 2.4: Associations with SNPs in ABCG2 in Conditional Analysis 
Associations between SNPs in ABCG2 and allopurinol response when the 
genotype for the missense variant rs2231142 is included in the model.  Top 5 
associated SNPs in the ABCG2 locus are shown. A1 represents the allele that the 
effect size is based on. Effect is defined as change in SUA (treated-untreated), 
therefore positive betas represent worse response to allopurinol 
 
Abbreviations: SNP, Single Nucleotide Polymorphism; SE, standard error 
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Figure 2.2: Forest Plots of Association with Top SNPs in ABCG2 and GREM2  
Forest plot representing the 95% confidence interval for effects of (A) BCRP 
Q141K and (B) GREM2 rs1934341 on allopurinol response. Effect is change in 
SUA (post-allopurinol – pre-allopurinol, mg/dL), meaning that positive effect sizes 
represent less change in SUA and worse response. Zero represents the average 
change in SUA for subjects with the reference allele.  “Total” values represent the 
95% confidence interval of inverse-variance weighted meta-analysis.   
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BioVU (Figure 2.2, beta=0.162 ± 0.035, p=3.22 x 10-6).  Although the association was 
not genome-wide significant, it was consistent across multiple cohorts and ethnicities.  
 
To further explore the effects of these SNPs on clinically meaningful outcomes, we 
explored additional phenotypes.  In particular, in the largest cohort, the Non-Hispanic 
Whites, we explored the effect of the top SNPs in ABCG2 and GREM2 on the ability to 
reach and maintain the rheumatologist recommended < 6 mg/dL SUA while adherent to 
allopurinol. We found that 26.1% of 1,316 Non-Hispanic White subjects were able to 
reach and maintain rheumatologist recommended SUA levels. Logistic regression 
analysis revealed that subjects carrying at least one BCRP Q141K allele were at a 
greater risk of not meeting the clinical endpoint, even when controlling for the covariates 
of dose, gender, and baseline SUA (Figure 2.3, OR= 0.71 ± 0.14, p= 0.015). In contrast, 
subjects carrying at least one allele of the GREM2 variant rs1934341 were more likely 
to achieve and maintain target SUA levels (Figure 2.3, OR= 1.35 ± 0.11, p= 0.0085).  
 
Previously, we showed that BCRP transports oxypurinol and allopurinol, so with a 
reduced function variant we would expect less efflux of oxypurinol by BCRP, thereby 
increasing plasma levels of the drug but increasing luminal levels. Thus, we 
hypothesized that oxypurinol may have a secondary mechanism of action as an inhibitor 
of uric acid reabsorption. GWAS have shown repeatedly that genetic variants in GLUT9 
and URAT1 significantly affect SUA levels, suggesting an important role of uric acid 
reabsorption in the determination of systemic uric acid levels (14).  In X. laevis oocytes, 
we found that oxypurinol can indeed inhibit the uptake of uric acid via GLUT9 more 
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potently than its inhibition of either OAT4 or URAT1 (Figure 2.4, IC50= 108 ± 17 uM for 
GLUT9, and IC50 > 1 mM for URAT1 and OAT4, Figure 2.5) (15). These data suggest 
that oxypurinol may inhibit uric acid reabsorption in the renal tubule via GLUT9. 
 
Discussion 
This study represents the largest genetic analysis of allopurinol response to date, and 
the first to show genome-wide level significance of the reduced function variant, BCRP 
Q141K, with hypouricemic response to allopurinol. Previously, in a smaller cohort, we 
showed that the reduced function variant BCRP Q141K associated with worse response 
to allopurinol, at near genome-wide levels.  In this study, with an expanded cohort and 
several new cohorts, we replicated our finding that this variant is associated with poor 
response to allopurinol with genome-wide significance (Figures 2.1 and 2.2). 
Importantly, we conducted conditional analyses, which suggest that BCRP Q141K is 
causal for poor response to allopurinol. The inclusion of two independent replication 
cohorts strengthened the association between the variant and response to allopurinol. 
Other groups have replicated this association as well, although these studies were not 
able to adjust for differences in baseline SUA and used a response variable rather than 
linear change in SUA (16, 17).  
 
Allopurinol, an older drug, remains first line therapy for gout.  In fact, though newer 
drugs have been developed and marketed, many of these are associated with serious 
adverse effects.  For example, in a recent multi-center non-inferiority trial in patients 
with gout and cardiovascular disease, febuxostat was associated with higher overall all- 
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Figure 2.3: Association of Top SNPs with Clinical Response 
Non-Hispanic White subjects were defined as responders (all treated SUA levels 
< 6 mg/dL) or non-responders based on their ability to reach and maintain 
rheumatologist recommended SUA levels while on allopurinol treatment. 
Response rate by (A) BCRP Q141K genotype (rs2231142) or (B) GREM2 
rs1934341 are shown, compared to the response of the overall cohort (red 
dashed line).  Logistic regression reveals that independent of dose, gender, and 
baseline SUA, these variants are predictors of a subject’s likelihood of reaching 
and maintaining healthy SUA levels.  
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Figure 2.4: Effects of Oxypurinol and Allopurinol on GLUT9-Mediated Uric Acid 
Uptake  
X. Laevis oocytes injected with GLUT9 mRNA were incubated with [14C]-uric acid 
and increasing amounts of allopurinol (red) and oxypurinol (black). Oxypurinol 
was able to inhibit GLUT9-mediated uptake of uric acid with an IC50 of 108 ± 17 
µM, while allopurinol showed little to no inhibition of GLUT9.  
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Figure 2.5: Effects of Oxypurinol and Allopurinol on URAT1-Mediated Uric Acid 
Uptake 
[14C]-Uric acid uptake by empty vector and URAT1 transiently transfected cells.  
Experiments were performed for 10 minutes at 37°C using 10 µM unlabeled uric 
acid with our without inhibitor (1 mM allopurinol, 1 mM oxypurinol and 0.1 mM 
benzobromarone. Uptake values were normalized to total protein and expressed as 
a percentage of URAT1 uric acid uptake; each bar represents the mean uptake ± 
SD of one represented experiment.  
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cause mortality and cardiovascular mortality than allopurinol (18).  Further, first in class 
drugs developed to target reabsorptive uric acid transporters such as lesinurad have 
been associated with kidney stones and other sequelae.  Conversely, allopurinol seems 
to have beneficial effects on renal function, slowing disease progression in patients with 
chronic kidney disease (19). Thus, there has been increasing interest in allopurinol, as 
the drug appears to be beneficial for the treatment of gout as well as its sequelae.   
 
Unfortunately, many patients fail to achieve acceptable responses to the drug, even 
when adherent. Importantly, individuals with the BCRP Q141K variant were found to be 
less likely to achieve and maintain the rheumatologist recommended SUA level of 6 
mg/dL or less (Figure 2.3), putting them at an increased risk for developing 
comorbidities. Further, this finding was significant despite including covariates such as 
gender, dose, and baseline SUA. Collectively, these studies suggest that patients with 
the BCRP Q141K variant, which has minor allele frequencies of 9.4-29.1% in 
Europeans, Hispanics, and East Asians (20), either need to be on a higher dose of 
allopurinol or perhaps be prescribed concomitant or other medications for the treatment 
of gout  
 
Our trans-ethnic meta-analysis not only supported the association of BCRP Q141K with 
poor response to allopurinol in multiple ethnic groups, but revealed a novel suggestive 
association with genetic variants in GREM2.  For GREM2, subjects carrying the minor 
allele had a greater change in SUA on allopurinol and were significantly more likely to 
reach and maintain rheumatologist recommended SUA levels (Figure 2.3). GREM2 is a 
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secreted antagonist of BMP that has been shown to play a role in cell differentiation and 
limit inflammation after myocardial infarctions in mice (21-23). GREM2 has been 
previously shown to be upregulated in glomeruli of rats with diabetic kidney disease, 
and dysregulation of its target, BMP, has been linked to diabetic kidney nephropathy 
and cardiovascular disease (24, 25), suggesting a role for GREM2 in the development 
of common gout sequelae. Interestingly, GREM2 has not been shown to associate with 
baseline SUA levels or gout, suggesting that its role in improving allopurinol response is 
pharmacologic, related to allopurinol’s effects on uric acid lowering. Further research is 
needed to determine the mechanism by which these SNPs alter GREM2 expression 
and function, and allopurinol hypouricemic response.  
 
The finding that oxypurinol potently inhibited GLUT9-mediated uric acid uptake is an 
important addition to understanding the potential mechanisms of action of allopurinol 
and oxypurinol. In particular, we found that oxypurinol inhibited GLUT9-mediated uptake 
of uric acid with an IC50 of 108 µM, suggesting that oxypurinol may have a secondary 
mechanism of action as a uricosuric. Plasma oxypurinol levels on a typical 300 mg dose 
of allopurinol range from approximately 30-80 µM and it is possible that renal levels of 
oxypurinol (26, 27), may be comparable and inhibit GLUT9.  In this scenario, BCRP 
Q141K could indeed cause worse response to allopurinol because of the decreased 
secretion of oxypurinol and therefore reduced levels in the renal tubule resulting in 
decreased inhibition of GLUT9. In the intestine, GLUT9 is expressed with a high 
expression level on the basolateral membrane of enterocytes, and appears to 
participate in intestinal excretion of uric acid (28). A reduced function variant of BCRP, 
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also expressed in enterocytes (29), would result in higher levels of allopurinol and 
oxypurinol within the enterocyte, and potentially increased inhibition of intestinal 
GLUT9-mediated intestinal excretion of uric acid. Both the renal and intestinal 
mechanisms are speculative and need further investigation. 
 
There are limitations to our findings in addition to those previously addressed.  First, as 
BCRP Q141K is associated with higher baseline SUA (14), it is possible that the variant 
associated with allopurinol response by affecting baseline SUA, or that patients carrying 
this variant have a worse disease overall and therefore do not respond as well.  
However, we adjusted for baseline SUA in our model to adjust for the effects of the 
variant on baseline SUA.  Further, genetic variants in other renal uric acid transporters 
including GLUT9 and URAT1 did not associate with allopurinol response adjusted for 
baseline SUA. This is also true of many other genes that associate with SUA levels that 
we do not see in our results (Table 2.5).  In fact, BCRP Q141K does not associate with 
baseline SUA in our cohort at genome-wide significance (Table 2.6). These data 
support an independent association of ABCG2 with response to allopurinol. Second, 
adherence to allopurinol is a large problem and one that could also cause non-
response. To address this, we have accounted for non-adherence using prescription 
refills, and only allowed subjects included in the analysis to go one week in between 
prescriptions. Finally, our investigation into the effects of ABCG2 and GREM2 variants 
on long-term control of SUA on allopurinol is limited by follow-ups reported in the EHR, 
which varied greatly among patients.  
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Variant Effect Allele Gene SUA Levels Allo Response  Beta SE P 
rs1471633 A PDZK1 + - 0.0048 0.04 0.9 
rs11264341 T TRIM46 - + 0.039 0.04 0.35 
rs1260326 T GCKR + - 0.069 0.04 0.083 
rs17050272 A INHBB + - 0.057 0.04 0.16 
rs653178 T ATXN2 - - 0.02 0.04 0.63 
rs6770152 T SFMBT1 - + -0.024 0.04 0.54 
rs12498742 A SLC2A9 + - 0.15 0.06 0.0052 
rs2231142 T ABCG2 + - 0.29 0.05 5.40 x 10-9 
rs17632159 C TMEM171 - - 0.038 0.04 0.39 
rs675209 T RREB1 + + -0.064 0.04 0.14 
rs1165151 T SLC17A1 - + -0.025 0.04 0.52 
rs729761 T VEGFA - + -0.014 0.05 0.76 
rs1178977 A BAZ1B + + -0.094 0.05 0.07 
rs17786744 A STC1 - - 0.044 0.04 0.27 
rs10480300 T PRKAG2 + + -0.013 0.05 0.78 
rs2941484 T HNF4G + - 0.049 0.04 0.21 
rs10821905 A A1CF + - 0.014 0.05 0.77 
rs1171614 T SLC16A9 - + -0.057 0.05 0.27 
rs2078267 T SLC22A11 - - 0.024 0.04 0.57 
rs478607 A NRXN2 - - 0.012 0.05 0.83 
rs7976059 T ACVR1B + + -0.036 0.04 0.39 
rs1394125 A UBE2Q2 + - 0.049 0.04 0.25 
rs3741414 T INHBC - + -0.0064 0.05 0.9 
Table 2.5: Top SNPs Associated with Uric Acid Levels and Their Association with 
Allopurinol Response 
SNPs that have been associated with SUA in Kottgen, et al (14), p < 5 x 10-8) and 
their associations with allopurinol response. Directionality for both SUA levels and 
allopurinol response is shown, with (-) corresponding to lower SUA levels and 
better allopurinol response while (+) corresponds to higher SUA levels and worse 
allopurinol response.  
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Variant Effect 
Allele 
Gene Beta SE P 
rs1471633 A PDZK1 0.076 0.05 0.10 
rs11264341 T TRIM46 -0.083 0.05 0.091 
rs1260326 T GCKR 0.059 0.05 0.21 
rs17050272 A INHBB -0.024 0.05 0.61 
rs653178 T ATXN2 -0.075 0.05 0.12 
rs6770152 T SFMBT1 0.088 0.05 0.06 
rs12498742 A SLC2A9 0.18 0.06 5.2 x 10-3 
rs2231142 T ABCG2 0.224 0.06 1.5 x 10-4 
rs17632159 C TMEM171 0.065 0.05 0.21 
rs675209 T RREB1 0.078 0.05 0.13 
rs1165151 T SLC17A1 -0.020 0.05 0.68 
rs729761 T VEGFA -0.013 0.06 0.82 
rs1178977 A BAZ1B 0.028 0.06 0.65 
rs17786744 A STC1 0.020 0.05 0.67 
rs10480300 T PRKAG2 0.13 0.06 0.02 
rs2941484 T HNF4G -0.010 0.05 0.82 
rs10821905 A A1CF -0.042 0.06 0.47 
rs1171614 T SLC16A9 -0.11 0.06 0.064 
rs2078267 T SLC22A11 -0.076 0.05 0.13 
rs478607 A NRXN2 0.057 0.06 0.37 
rs7976059 T ACVR1B 0.042 0.05 0.39 
rs1394125 A UBE2Q2 0.065 0.05 0.20 
rs3741414 T INHBC 0.034 0.06 0.56 
rs6598541 A IGF1R -0.016 0.05 0.74 
rs7193778 T NFAT5 -0.062 0.07 0.35 
rs7224610 A HLF -0.015 0.05 0.77 
rs7188445 A MAF 0.051 0.05 0.31 
rs7953704 A B3GNT4 0.089 0.05 0.05 	
Table 2.6: Association of SNPs with Baseline Uric Acid Levels in this Study 
Cohort 
SNPs that have been associated with SUA in Kottgen, et al (14), p < 5 x 10-8) 
and their association with baseline SUA levels in our cohort.  
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With the growing prevalence of gout there has been a resurgence of interest in its 
treatment. Allopurinol is first-line treatment but inadequate response and 
hypersensitivity reactions continue to be a concern for its use. With the higher rate of 
all-cause mortality in gout patients associated with febuxostat therapy when compared 
to allopurinol (18), the potential problems with the development of kidney stones for 
lesinurad, and higher costs for new drugs, there remains high interest in characterizing 
the factors that predict improved response to allopurinol. Our data pave the way to 
using genetic information to better predict response to allopurinol and select optimal 
therapy for gout.  
 
Methods: 
Study Cohorts 
ALLO1 and ALLO2: 
Data from the Kaiser Permanente Research Program on Genes, Environment and 
Health (RPGEH) were gathered for analysis. ALLO1 is made up of subjects gathered as 
a part of the Epidemiology Research on Adult Health and Aging (GERA) Cohort, while 
ALLO2 is made up of subjects whose DNA was genotyped as a part of this project and 
not the GERA cohort. Subjects with both treated and baseline SUA readings were 
included in the final study population. Baseline readings were considered any SUA 
reading within 1.5 years before allopurinol initiation and treated readings were 
considered any reading after 4 days of allopurinol initiation but no more than 7 days 
after termination.  If multiple baseline SUA readings existed, the closest to allopurinol 
initiation was chosen. If multiple treated readings or treatment periods met inclusion 
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criteria, the first was chosen. The study population consisted of 3,517 subjects, 2,820 of 
which were Non-Hispanic Whites. The average age of the cohort was approximately 67 
years old at the time of sample collection for genotyping.  
 
BioVU: 
Data from BioVU (Vanderbilt University Medical Center Biorepository (11)) meeting 
inclusion criteria were gathered for analysis as a part of the Pharmacogenomics 
Research Network (PGRN)  PGPop (PharmacoGenomic discovery and replication in 
very large patient POPulations) collaboration. Inclusion criteria were identical to those of 
ALLO1, except that if multiple treated readings existed, the median was taken. 
Information from 601 subjects was gathered for analysis, 481 of which were Non-
Hispanic Whites. The average age of the cohort was approximately 53 at the time of 
baseline SUA reading. 
 
MARSH: 
Data from Marshfield Personalized Medicine Research Project (12) meeting inclusion 
criteria were gathered for analysis as a part of the PGRN PGPop collaboration. 
Inclusion criteria were identical to those of ALLO1. Information from 328 subjects was 
gathered for analysis, 312 of which were Non-Hispanic Whites. The average age of the 
cohort was approximately 67 at the time of baseline SUA reading.  
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Genotyping and Imputation 
Detailed methods on the genotyping and imputation of ALLO1 can be found in Kvale, et 
al (30). Briefly, subjects were genotyped on ethnic specific Affymetrix Axiom World 
Arrays. 
 
For subjects in ALLO2, DNA extracted from saliva or blood was sent to RIKEN Institute 
for genotyping on the Illumuna Infinium OmniExpressExome chip according to standard 
protocol. Samples with a call rate <0.98 were excluded. After reclustering without these 
samples, SNPs with a call rate <0.99 were excluded from analysis. Four parameters 
were examined to determine and exclude ambiguous calls: cluster separation score, 
mean fluorescence difference,, mean fluorescence angle, and frequency of excess 
heterozygotes.  
 
Post QC genotyped data for ALLO1 and ALLO2 were imputed using the 1000 Genomes 
Project (31) as a cosmopolitan reference panel. As a quality control, we used the r2 info 
metric, which estimates the correlation of the true genotype to the imputed genotype, 
and set a cutoff of r2>0.3 for inclusion in our analyses.  
 
Subjects from BioVU and MARSH were genotyped at top loci in ABCG2 using 
Sequenom MassARRAY genotyping platform according to protocol. A call rate of 90% 
was used as a quality control cutoff for both SNPs and subjects. No SNPs showed 
evidence of HapMap Mendelian Errors and Concordance with HapMap samples was 
100%.  
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Samples from a subset of subjects from BioVU were also used to replicate the 
association with SNPs in GREM2. These samples were genotyped as a part of the 
BioVU program, described in more detail in Roden, et al (11). Briefly, samples were 
genotyped across 4 Illumina platforms (MEGeX, OMNI-Quad, OMNI5M, 660w). Post 
QC genotype data was imputed using the HRCv1.1 (32) reference panel and any SNP 
with info metric r2 < 0.5 was excluded from analysis. 355 subjects of the BioVU cohort 
had been genotyped as a part of this effort, and data for rs1934341 were gathered for 
replication analysis.   
 
Genetic Ancestry 
Detailed methods on the computation of principal components for ALLO1 can be found 
in Banda, et al (33). 
 
Plink v1.90 (34) was used to compute principal components for ALLO2. Subjects were 
split by ethnicity and due to small sample size, each ethnic group was combined with 
appropriate ancestral ethnicities from the Human Genome Diversity Project (35) to 
calculate principal components. These PCs were used in GWAS to adjust for genetic 
ancestry.  
 
Genome-wide Association Study and Meta-Analyses 
Association analysis was conducted using a linear regression model in PLINK v1.90 
(34). The phenotype was calculated as the change in SUA (treated-baseline). 
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Covariates were added to the model in a stepwise fashion and models were evaluated 
against the baseline model using ANOVA with a cutoff of p<0.05. This generated the 
final model: 
 
 Change in SUA ~ Baseline SUA + Age at Initiation + Concomitant Diuretics + 
 Dose + Gender + eGFR + Percent Days Nonadherent + Principal Components  
 
The top 10 principal components were included for the Non-Hispanic White subjects, 
and the top 6 for all other ethnicities to correct for population stratification. Variants with 
greater than 10% missing genotypes or less than 0.01 minor allele frequency were 
filtered from analysis.  
 
Regression was done in each individual ethnic group and cohort then results were 
combined via fixed effects inverse-variance weighted meta-analysis using GWAMA 
(36). As a quality control step, top hits were evaluated for extreme departure from 
Hardy-Weinberg Equilibrium.   
 
R v3.4.0 (37) was used for phenotype generation and visualization. 
 
Analysis on baseline SUA was performed in a similar manner, using the following 
model: 
Baseline SUA ~ Age + Concomitant Diuretics + Gender + eGFR + BMI + 
Principal Components  
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Conditional Analysis 
Analysis was performed in the same manner as for allopurinol response GWAS, 
including the genotype for rs2231142 as an additional covariate. Linear regression was 
performed in Non-Hispanic White population of both ALLO1 and ALLO2 separately and 
combined via inverse-variance weighted meta-analysis.  
 
Logistic Regression Analysis on Maintaining SUA < 6 mg/dL 
Information from each subject’s treatment period was gathered for analysis, and 1,316 
Non-Hispanic White subjects with more than one treated reading were gathered for 
analysis. Subjects were defined as having complete (all treated readings below the 
recommended 6 mg/dL) or inadequate (no or some readings below this threshold) 
clinical response to allopurinol. Covariates were tested in a similar manner to uric acid 
change, generating the final model: 
 
Clinical Response ~ Baseline SUA + Gender + Dose  
 
Logistic regression was performed using R v3.4.0 (37) on this model with the genotype 
for BCRP Q141K (rs2231142) and GREM2 rs1934341.  
 
X.laevis oocyte GLUT9 inhibition studies 
A pOX-hGLUT9b plasmid, which contains the sequence of human GLUT9 (hGLUT9b, 
NM_001001290.1) cloned into pOX vector (https://www.addgene.org/vector-
database/3780/), was used to generate hGLUT9b capped cRNA. pOX-hGLUT9b 
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plasmid was linearized using NotI restriction enzyme and cRNA generated using the 
mMessage mMachine T7 kit (Thermo Fisher Scientific). Ecocyte Bio Science LLC 
(Austin, TX) provided stage VI, defollicuted oocytes along with oocyte injection services. 
Five to ten oocytes were selected per condition and each oocyte was injected with 50 
nL of saline or hGLUT9b cRNA (40 ng per oocyte). Oocytes were incubated on a shaker 
at 18°C in Modified Barth’s solution with gentamicin (NaCl 88 mM, KCl 1mM, MgSO4 
1mM, HEPES 5 mM, NaHCO3 2.5 mM, CaCl2 0.7mM, Gentamicin 100 µg/mL) that was 
replenished every 24 hours. 48 hours post-injection, 20-minute uptake assays were 
performed. Modified Barth’s solution containing trace amount of labeled [14C]-uric acid 
(American Radiolabeled Chemicals, ARC 0513A)  (10µM total of uric acid) with 
increasing concentrations of oxypurinol or allopurinol (0 - 1mM dissolved in 0.1 M 
sodium hydroxide) was used as the uptake buffer. After uptake, oocytes were washed 5 
times in ice-cold buffer then lysed in 0.5 mL of 1% SDS solution for at least 1 hour. 
Radioactivity (disintegrations per minute) was measured using a liquid scintillation 
counter. IC50 values for oxypurinol and allopurinol were calculated by non-linear 
regression using GraphPad Prism 7 (La Jolla, CA).  Figures are representative of 3 
experiments using 5-10 oocytes per condition per experiment.   
 
HEK293 URAT1 inhibition studies  
The full-length cDNA for URAT1 (NM_144585) was purchased from Origene, which is 
available in pCMV6-Entry vector backbone (CAT#: RC217294).  The vector containing 
the URAT1 cDNA or vector only, were transiently transfected to Flp-In-293® (HEK-293) 
cells (Invitrogen) grown on a 24-well poly-D-lysine plate. Cells grown at 37°C with 5% 
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CO2 were transfected with the vector only (pCMV6-Entry) or pCMV6-Entry-URAT1 
vector and uptake studies were performed 40-48 hours after transfection.  The 
manufacturer’s protocol for Lipofectamine LTX (Invitrogen) was followed, where each 
well of the 24-well poly-D-lysine plate contained 500 ng of the plasmid DNA and 1 µL of 
the Lipofectamine LTX (Invitrogen). 
Uptake experiments using [14C]-uric acid (American Radiolabeled Chemicals, catalog 
number ARC 0513A) were performed using cells transiently expressing vector only (EV) 
or hURAT1. Cells were washed twice with HBSS buffer and incubated with chloride-free 
buffer (125 mM sodium gluconate, 4.8 mM potassium gluconate, 1.2 mM K2HPO4, 1.2 
mM MgSO4, 1.3 mM calcium gluconate, and 25 mM HEPES/Tris; pH ≈ 7.4) for 5 min 
before uptake studies commenced. Warm chloride-free uptake buffer containing 10 µM 
of unlabeled uric acid and trace amount of radiolabeled uric acid was added to the cells, 
as well as inhibitor compound as indicated in the figure legends.  After 10 minutes, the 
cells were quickly washed twice with ice-cold HBSS buffer followed by the addition of 
0.8 mL of lysis buffer (0.1% SDS/0.1 N NaOH).  Uptake values were determined using 
liquid scintillation counter and were normalized to the total protein in each well as 
determined using a bicinchoninic acid (BCA) protein assay. Two independent 
experiments were performed and supplemental figure represents the results from one of 
the experiments. 
 
  
  65 
References 
(1) Kuo, C.F., Grainge, M.J., Zhang, W. & Doherty, M. Global epidemiology of gout: 
prevalence, incidence and risk factors. Nature reviews Rheumatology  11, 649-
62 (2015). 
(2) Essex, M.N., Hopps, M., Bienen, E.J., Udall, M., Mardekian, J. & Makinson, G.T. 
Evaluation of the Relationship Between Serum Uric Acid Levels and 
Cardiovascular Events in Patients With Gout: A Retrospective Analysis Using 
Electronic Medical Record Data. Journal of clinical rheumatology : practical 
reports on rheumatic & musculoskeletal diseases  23, 160-6 (2017). 
(3) Paul, B.J., Anoopkumar, K. & Krishnan, V. Asymptomatic hyperuricemia: is it 
time to intervene? Clin Rheumatol  36, 2637-44 (2017). 
(4) Bardin, T. & Richette, P. Impact of comorbidities on gout and hyperuricaemia: an 
update on prevalence and treatment options. BMC Med  15, 123 (2017). 
(5) Roughley, M.J., Belcher, J., Mallen, C.D. & Roddy, E. Gout and risk of chronic 
kidney disease and nephrolithiasis: meta-analysis of observational studies. 
Arthritis Res Ther  17, 90 (2015). 
(6) Graham, G.G., Stocker, S.L., Kannangara, D.R.W. & Day, R.O. Predicting 
Response or Non-response to Urate-Lowering Therapy in Patients with Gout. 
Current rheumatology reports  20, 47 (2018). 
(7) Becker, M.A. et al. Febuxostat compared with allopurinol in patients with 
hyperuricemia and gout. The New England journal of medicine  353, 2450-61 
(2005). 
(8) Stamp, L.K. et al. Impaired response or insufficient dosage? Examining the 
potential causes of "inadequate response" to allopurinol in the treatment of gout. 
Seminars in arthritis and rheumatism  44, 170-4 (2014). 
(9) Wen, C.C. et al. Genome-wide association study identifies ABCG2 (BCRP) as an 
allopurinol transporter and a determinant of drug response. Clinical 
pharmacology and therapeutics,  (2015). 
(10) Resource for Genetic Epidemiology Research on Adult Health and Aging (GERA) 
dbGaP study Accession phs000674.v1.p1. 
(11) Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to 
enable personalized medicine. Clinical pharmacology and therapeutics  84, 362-
9 (2008). 
(12) McCarty, C.A., Wilke, R.A., Giampietro, P.F., Wesbrook, S.D. & Caldwell, M.D. 
Marshfield Clinic Personalized Medicine Research Project (PMRP): design, 
methods and recruitment for a large population-based biobank. Per Med  2, 49-
79 (2005). 
(13) Ward, L.D. & Kellis, M. HaploReg: a resource for exploring chromatin states, 
conservation, and regulatory motif alterations within sets of genetically linked 
variants. Nucleic Acids Res  40, D930-4 (2012). 
(14) Kottgen, A. et al. Genome-wide association analyses identify 18 new loci 
associated with serum urate concentrations. Nature genetics  45, 145-54 (2013). 
(15) Iwanaga, T., Kobayashi, D., Hirayama, M., Maeda, T. & Tamai, I. Involvement of 
uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor 
  66 
oxypurinol induced by a uricosuric agent, benzbromarone. Drug metabolism and 
disposition: the biological fate of chemicals  33, 1791-5 (2005). 
(16) Roberts, R.L. et al. ABCG2 loss-of-function polymorphism predicts poor 
response to allopurinol in patients with gout. Pharmacogenomics J  17, 201-3 
(2017). 
(17) Wallace, M.C. et al. Association between ABCG2 rs2231142 and poor response 
to allopurinol: replication and meta-analysis. Rheumatology  57, 656-60 (2018). 
(18) White, W.B. et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients 
with Gout. The New England journal of medicine  378, 1200-10 (2018). 
(19) Panchapakesan, U. & Pollock, C. Drug repurposing in kidney disease. Kidney Int  
94, 40-8 (2018). 
(20) Yates, A. et al. Ensembl 2016-Release 90. Nucleic Acids Res  44, D710-6 
(2016). 
(21) Sanders, L.N. et al. BMP Antagonist Gremlin 2 Limits Inflammation After 
Myocardial Infarction. Circ Res  119, 434-49 (2016). 
(22) Nolan, K. & Thompson, T.B. The DAN family: modulators of TGF-beta signaling 
and beyond. Protein Sci  23, 999-1012 (2014). 
(23) Li, W. et al. Gremlin2 Regulates the Differentiation and Function of Cardiac 
Progenitor Cells via the Notch Signaling Pathway. Cell Physiol Biochem  47, 579-
89 (2018). 
(24) Zou, H.H., Yang, P.P., Huang, T.L., Zheng, X.X. & Xu, G.S. PLK2 Plays an 
Essential Role in High D-Glucose-Induced Apoptosis, ROS Generation and 
Inflammation in Podocytes. Sci Rep  7, 4261 (2017). 
(25) Kim, M. & Choe, S. BMPs and their clinical potentials. BMB Rep  44, 619-34 
(2011). 
(26) Stocker, S.L. et al. The pharmacokinetics of oxypurinol in people with gout. 
British journal of clinical pharmacology  74, 477-89 (2012). 
(27) Wright, D.F., Stamp, L.K., Merriman, T.R., Barclay, M.L., Duffull, S.B. & Holford, 
N.H. The population pharmacokinetics of allopurinol and oxypurinol in patients 
with gout. European journal of clinical pharmacology  69, 1411-21 (2013). 
(28) DeBosch, B.J., Kluth, O., Fujiwara, H., Schurmann, A. & Moley, K. Early-onset 
metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. 
Nature communications  5, 4642 (2014). 
(29) Meyer zu Schwabedissen, H.E. & Kroemer, H.K. In vitro and in vivo evidence for 
the importance of breast cancer resistance protein transporters 
(BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol, 325-71 (2011). 
(30) Kvale, M.N. et al. Genotyping Informatics and Quality Control for 100,000 
Subjects in the Genetic Epidemiology Research on Adult Health and Aging 
(GERA) Cohort. Genetics  200, 1051-60 (2015). 
(31) Genomes Project, C. et al. An integrated map of genetic variation from 1,092 
human genomes. Nature  491, 56-65 (2012). 
(32) McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype 
imputation. Nature genetics  48, 1279-83 (2016). 
(33) Banda, Y. et al. Characterizing Race/Ethnicity and Genetic Ancestry for 100,000 
Subjects in the Genetic Epidemiology Research on Adult Health and Aging 
(GERA) Cohort. Genetics  200, 1285-95 (2015). 
  67 
(34) Purcell, S. et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. American journal of human genetics  81, 559-75 (2007). 
(35) Cavalli-Sforza, L.L. The Human Genome Diversity Project: past, present and 
future. Nature reviews Genetics  6, 333-40 (2005). 
(36) Magi, R. & Morris, A.P. GWAMA: software for genome-wide association meta-
analysis. BMC bioinformatics  11, 288 (2010). 
(37) R Core Team. R: A language and environment for statistical computing. In: R 
Foundation for Statistical Computing  (Vienna, Austria, 2017). 
 
 
  
  68 
Chapter 3: Reduced Function BCRP Q141K and its Effects on Allopurinol PK-PD  
 
Introduction 
Recently, there has been a resurgence of interest in the treatment of gout, a painful 
inflammatory arthritis caused by high serum uric acid (SUA) levels. Beyond the pain and 
discomfort this disease causes for its patients, gout has been shown to be an 
independent risk factor for a number of deadly comorbidities such as heart disease, 
chronic kidney disease, and stroke (1-4). Allopurinol, which was developed as a 
xanthine oxidase inhibitor to block the formation of uric acid, is the first-line treatment for 
chronic gout. Response to allopurinol is highly variable, with studies showing as few as 
21% of patients reaching an acceptable treatment endpoint (5). While there are other 
drugs on the market for the treatment of gout, such as lesinurad and febuxostat, each 
drug comes with its own risks and drawbacks. Lesinurad has been linked to an 
increased risk for kidney stones, and is indicated for use in conjunction with allopurinol 
rather than as a replacement therapy (6). Febuxostat was recently linked to higher all-
cause mortality in gout patients when compared to allopurinol, although allopurinol 
comes with its own risks including Stevens-Johnson Syndrome (7, 8). Therefore, it is of 
utmost importance to identify the optimal medication for gout patients.  
 
In an effort to identify patient populations at risk for inadequate response to allopurinol, 
numerous studies have been performed to create and characterize a precision dosing 
model. Factors such as baseline SUA, diuretic use, creatinine clearance, and body 
weight have been examined for their use in predicting pharmacodynamic response, but 
  69 
results have been conflicting (9-11). Recently, genome-wide association studies 
(GWAS) have implicated genetic variants within ABCG2, which encodes the efflux 
pump BCRP, as a determinant of allopurinol response. Specifically, the missense 
variant, BCRP Q141K, which encodes a reduced-function BCRP, has been linked to 
worse response to allopurinol (12, 13). Interestingly, oxypurinol, the active metabolite of 
allopurinol, was identified as a BCRP substrate, suggesting that the relationship 
between BCRP Q141K and pharmacologic response may be due to pharmacokinetic 
differences caused by reduced BCRP-mediated transport of oxypurinol.  
 
BCRP acts as an efflux pump on the apical membrane of the renal tubule, intestine, and 
liver, and BCRP Q141K has been shown to alter the pharmacokinetics and 
pharmacodynamics of many of its substrates, most notably rosuvastatin (14). However, 
the variant is typically associated with increased systemic levels and pharmacologic 
response of its substrates, making the link between BCRP Q141K and worse response 
to allopurinol an enigma. In this study, we aimed to characterize the relationship 
between BCRP Q141K and allopurinol disposition and response through an intensive 
pharmacokinetic-pharmacodynamic study in healthy volunteers. Specifically, we aimed 
to identify differences in allopurinol exposure and clearance between subjects with the 
BCRP Q141K genotype and those with the reference allele, as well as any differences 
in their hypouricemic response.  
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Results 
Healthy volunteers of European or Asian ancestry were screened for participation in this 
study. These ethnicities were chosen due to the high minor allele frequencies in Asian 
and European ancestries, 29% and 9%, respectively (15). Of the 178 subjects 
screened, 19 were enrolled in the study. Most subjects were excluded based on ABCG2 
genotype, HLA-B*58:01 genotype, and concomitant medications. Eight subjects 
completed the multi-dose study design, while 11 completed the single dose design, 
which was used to increase enrollment and subject interest (Figure 3.1). Demographics 
of the study subjects by genotype can be found in Table 3.1. There were no significant 
differences between gender (p=0.35), age (p=0.29), or body weight (p=0.49) between 
genotype groups. Estimated glomerular filtration rate (eGFR) was significantly different 
between genotype groups using a dominant genetic model (p=0.02), although all 
subjects exhibited a healthy eGFR (>60 mL/min). The majority of the subjects were of 
East Asian ancestry.  
 
Allopurinol was well tolerated in all subjects. Pharmacokinetic parameters for allopurinol 
split by genotype are summarized in Table 3.2, while oxypurinol parameters are 
summarized in Table 3.3.  The pharmacokinetics of allopurinol did not significantly differ 
between genotype groups (AUC, p=0.12 ; CL/F, p=0.85 ; V/F p=0.58) For oxypurinol, no 
significant differences in the pharmacokinetic parameters between genotype groups 
were detected (AUC, p= 0.39; CL/F, p=0.79 ; V/F p=0.45) with the exception of half-life 
(T1/2). In particular, T1/2 was significantly longer in subjects with the BCRP Q141K variant 
using a dominant genetic model (19.1 ± 0.5 vs 23.3 ± 0.2, p=0.02).  As half-life is  
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 Draw
Figure 3.1: Study Design 
Study design for (a) multi-dose and (b) single dose clinical study. Each clinic 
visit includes 24 hours of intensive blood and urine sampling. Eleven 
participants completed the single dose design while eight participants completed 
the multi-dose design.  
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dependent on both volume of distribution (V) and clearance (CL), this effect may be due 
to the trend towards a larger V and lower CL in subjects with the A allele (Table 3.3)  
 
Consistent with results from larger studies, the BCRP Q141K genotype was significantly 
associated with higher baseline SUA levels in our subjects (Figure 3.2, p=0.001).  To 
investigate the pharmacodynamic effect of allopurinol, we characterized change in SUA 
levels from baseline. Minimum SUA level following a single dose of allopurinol was used 
to calculate percent change from baseline (Table 3.4). Consistent with the association 
detected via GWAS, subjects with the BCRP Q141K genotype tend to have less change 
in SUA levels following allopurinol treatment, though this trend is not significant using a 
dominant genetic model (26.7 ± 0.8 vs 23.7 ± 0.5, p=0.27). 
 
Discussion 
The reduced function variant BCRP Q141K is increasingly being recognized for its 
effects on the pharmacokinetics and pharmacodynamics (PK-PD) of its substrates. 
Previously, the variant has been identified as a determinant of allopurinol’s 
hypouricemic response through GWAS (12) and in candidate gene studies(13, 16). The 
current study provides the first investigation into the relationship between BCRP Q141K 
and allopurinol PK-PD in a prospective clinical trial.   
 
Our chief finding was that BCRP genotype associates with a slightly but significantly 
longer half-life of oxypurinol in individuals carrying the reduced function variant. As  
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Table 3.1: Study Cohort 
Demographics for the study cohort split by BCRP Q141K genotype. No 
significant differences were detected in age or weight between the genotype 
groups. There was a significant difference in eGFR between the groups, but all 
subjects exhibited a healthy eGFR (>60 mL/min). *p<0.05 in dominant genetic 
model  
  
 
Genotype1
EAS SAS FLP EUR Male Female
CC 5 2 1 0 4 4
CA 5 1 1 1 6 2
AA 2 0 1 0 2 1
CC
CA
AA
30.0	(24.8	-	34.0) 67.5	(60.8	-	80.6) 113.5	(106.2	-	122.6)*
27.0	(24.0	-	30.5) 72.6	(69.3	-	77.1) 110.7	(110.1	-	116.7)*
Number
Median	(Interquartile	Range)
Age	(years) Weight	(kg) eGFR2	(mL/min)
24	(22.5	-	30.3) 65.5	(57.0	-	71.0) 126.5	(123.9	-	129.2)
Abbreviations:	EAS,	East	Asian;	SAS,	South	Asian;	FLP,	Filipino;	EUR,	European;	eGFR,	estimated	glomerular	filtration	rate	1BCRP	Q141K	(rs2231142)	genotype	where	C	is	the	major	allele	and	A	is	the	minor	allele	2eGFR	calculated	from	serum	creatinine	levels	using	CKD-EPI	equation	
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Table 3.2: Pharmacokinetic Parameters of Allopurinol Split by BCRP Q141K 
Genotype 
Pharmacokinetic parameters of allopurinol as determined by non-
compartmental analysis. No significant differences were detected between 
genotype groups. 
Genotype1	 AUC	 CL/F	 V/F	 T1/2	 Cmax	 Tmax	 FE	
	
(µg*hr/mL)	 	(L/hr)	 (L)	 (hr)	 (µg/mL)	 (hr)	
	CC	(n=8)	 7.1	±	0.8	 91.6	±	3.7	 137	±	5.9	 1.05	±	0.02	 1.45	±	0.04	 1.30	±	0.08	 0.506	±	0.02	
CA	(n=8)	 32.3	±	5.3	 89.2	±	4.3	 152	±	7.2	 1.20	±	0.03	 1.78	±	0.20	 1.23	±	0.06	 0.450	±	0.05	
AA	(n=3)	 12.0	±	4.7	 87.4	±	16	 147	±	28	 1.16	±	0.12	 1.55	±	0.26	 1.61	±	0.22	 0.467	±	0.08	
	
Abbreviations:	AUC,	area	under	the	curve;	CL,	clearance;	V,	volume	of	distribution;	F,	bioavailability;	Cmax,	maximum	concentration;	
Tmax,	time	of	maximum	concentration;	FE,	fractional	excretion	
1BCRP	Q141K	(rs2231142)	genotype	where	C	is	the	major	allele	and	A	is	the	minor	allele	
	
Table 3.3: Pharmacokinetic Parameters of Oxypurinol Split by BCRP Q141K 
Genotype 
Pharmacokinetic parameters of oxypurinol as determined by non-
compartmental analysis, assuming 90 mg of oxypurinol formation per 100 mg 
allopurinol. *p<0.05 in a dominant genetic model.  
Genotype	 AUC	 CL/F	 V/F	 T1/2	 Cmax	 Tmax	 FE	
	
(µg*hr/mL)	 	(L/hr)	 (L)	 (hr)	 (µg/mL)	 (hr)	
	CC	(n=8)	 361	±	33		 2.26	±	0.15	 61.1	±	4.0	 19.1	±	0.47	 6.01	±	0.16	 3.96	±	0.25	 0.140	±	0.01	
CA	(n=8)	 512	±	53	 2.23	±	0.08	 76.9	±	3.1	 23.9	±	0.40*	 6.29	±	0.19	 4.79	±	0.33	 0.127	±	0.01	
AA	(n=3)	 463	±	163	 1.86	±	0.28	 57.5	±	7.5	 21.9	±	0.59*	 6.38	±	0.78	 4.94	±	0.61	 0.138	±	0.01	
	
Abbreviations:	AUC,	area	under	the	curve;	CL,	clearance;	V,	volume	of	distribution;	F,	bioavailability;	Cmax,	maximum	concentration;	
Tmax,	time	of	maximum	concentration;	FE,	fractional	excretion	
1BCRP	Q141K	(rs2231142)	genotype	where	C	is	the	major	allele	and	A	is	the	minor	allele	
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Figure 3.2: Baseline Serum Uric Acid (SUA) Levels by BCRP Q141K Genotype 
Dot plot of baseline serum uric acid (SUA) levels by BCRP Q141K genotype. 
Plots represent mean ± std. error. *P<0.05 in dominant genetic model 
* * 
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Table 3.4: Pharmacodynamic Parameters Split by BCRP Q141K Genotype 
Pharmacodynamic parameters after a single dose of allopurinol. *p<0.05 in 
dominant genetic model.  
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half- life is dependent on both clearance and volume of distribution, we interpreted the 
effect of the variant as being a result of slight but not significant effects on volume and 
clearance of oxypurinol. There was no significant difference in fractional excretion, renal 
clearance or CL/F of oxypurinol between genotype groups, but there was a trend for 
each of these values to be slightly higher in the individuals homozygous for the C-allele. 
Conversely, there was a trend for V/F to be slightly lower in these individuals compared 
with the other two genotype groups.  These trends, though not significant, likely explain 
the significantly shorter half-life of oxypurinol in the individuals homozygous for the C-
allele. Differences in eGFR between genotype groups may have contributed to the 
observed trends in CL/F, as data from BioBank Japan suggest that the C allele may 
associate with higher eGFR in Asian subjects (17), similar to the effects we observed in 
our study. BCRP is widely expressed in tissues, including the intestine, colon, liver, 
kidney, brain, and thyroid (18).  A reduced-function variant of BCRP could cause 
increased oxypurinol levels in these tissues by reducing BCRP-mediated efflux. In this 
study, V/F does not show a significant difference between genotype groups, but 
bioavailability would likely be dependent on BCRP Q141K genotype, which may 
counteract the effects of genotype on the estimate of volume of distribution. Intravenous 
studies would be needed to directly determine the effect of genotype on volume and 
clearance without confounding by changes in bioavailability to determine the clinical 
significance of this finding.  
 
Though no significant effects of BCRP Q141K were observed in the pharmacodynamics 
of allopurinol, we observed a trend that subjects carrying the Q141K variant have a 
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smaller change in SUA on allopurinol than subjects without the variant (Table 3.4).   
This trend is consistent with previous GWAS and a recent study showing that including 
BCRP Q141K genotype into allopurinol dosing models could improve predictive 
capacity (19). Previously, we proposed that systemic levels of oxypurinol may not be 
associated with its hypouricemic response; rather tissue levels of the drug may be more 
predictive.  Specifically, oxypurinol levels in the renal tubule or the enterocytes could 
also be important for its mechanism of action as a potential uricosuric (12). Given that 
BCRP Q141K genotype does not associate with fractional excretion of oxypurinol, the 
hypothesis that enterocyte concentrations drive response is more plausible. 
Interestingly, a commentary by Stamp, et al (20) recently showed that BCRP Q141K 
does not associate with plasma oxypurinol concentrations when accounting for other 
factors such as dose, eGFR, and diuretic use, but does still associate with worse 
response to allopurinol (13). This further suggests that the interaction between BCRP 
Q141K and pharmacodynamic response to allopurinol may be independent of systemic 
pharmacokinetics, and depend more on its levels in enterocytes or other tissues.  
 
Our finding that baseline SUA significantly associated with BCRP Q141K is consistent 
with many previous studies (21-24).  Mechanistically, this association could occur 
through effects of the transporter in the kidney (i.e., reduced renal elimination of uric 
acid) or effects in the intestine (i.e., reduced intestinal elimination of uric acid), or both. 
Because the placebo arm of our study only included 8 participants, we are 
underpowered to address the issue of tissue specificity of the effects of BCRP Q141K 
on baseline SUA levels.  In a study of subjects with chronic kidney disease and 
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therefore very little kidney function, genetic variants in ABCG2 associated with SUA 
levels, consistent with the idea that intestinal BCRP contributes to the effects of ABCG2 
variants on SUA levels (25).  
 
There are a number of limitations to this study. First, using data from the population 
pharmacokinetics of oxypurinol (26), we are only 80% powered to detect approximately 
40% difference in oxypurinol clearance at a significance level of 0.05, meaning that 
there may be significant differences in PK parameters between genotype groups that 
went undetected in our study. Further, there was evidence of enterohepatic circulation 
of oxypurinol, as demonstrated by multiple peaks in a of oxypurinol levels in a number 
of subjects. This greatly affects Cmax and potentially AUC and half-life, which are used to 
identify relative differences in bioavailability and exposure between genotype groups. 
Thirdly, there was a substantial amount of missing data points for urine samples. 
However, we used only the cumulative urine after 24 hours to account for these missing 
timepoints, as they were due to inability of some of the subjects to urinate at specified 
times, rather than urine that had failed to be collected. This should effectively minimize 
any confounding by the differences in urine collection.  A final limitation is that 
allopurinol was dosed orally, as allopurinol for IV injection is only indicated for 
prevention of tumor lysis syndrome, limiting our ability to precisely detect effects of 
BCRP Q141K on bioavailability, and therefore on clearance and volume of distribution 
of the drug. 
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The renewed interest in the treatment of gout stems from its growing prevalence and 
severe sequelae. Allopurinol remains first-line treatment, but recent GWAS have 
indicated that subjects harboring the BCRP Q141K variant may not respond as well to 
allopurinol. This study suggests that the mechanism by which BCRP Q141K alters drug 
response and systemic uric acid levels is complex and may be attributed to tissue 
specific levels of the drug and uric acid, ultimately affecting pharmacodynamics of 
allopurinol. 
 
Methods 
Healthy Human Volunteers 
Healthy human volunteers between the ages of 18-50 were recruited for this study. All 
subjects were evaluated to be healthy on the basis of medical history provided by a 
study questionnaire. Volunteers were not taking any medications that are known to 
interact with uric acid levels, BCRP function, or allopurinol pharmacokinetics. Individuals 
with elevated liver enzymes (>1.5x normal range) or elevated creatinine concentrations 
(>1.5x normal range) were excluded. Individuals with abnormal platelet and white blood 
count levels were also excluded. Individuals carrying the HLA-B*58:01 allele were 
excluded from this study because of the increased risk for allopurinol-induced Stevens-
Johnson syndrome.  
 
Genotyping 
BCRP Q141K (rs2231142) was genotyped by TaqMan assay (Applied Biosystems, 
assay ID C__15854163_70, Foster City, CA). The reaction mixture consisted of 10 ng 
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DNA, 12.5 µL of TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA), 
1.25 µL of TaqMan genotyping assay mix, and 11.25 µL of distilled water. The cycling 
conditions were as follows: 95°C for 10 minutes and 40 cycles of 95°C for 15 seconds 
then 60°C for 1 minute. The reaction was run on a BioRad MyCycler (Bio-Rad, 
Hercules, CA) and allele discrimination determined by ABI 7900 Fast HT Sequence 
Detection Systems (Applied Biosystems, Foster City, CA).  
 
Clinical Study Procedures 
This study protocol was reviewed and approved by Western Institutional Review Board. 
Healthy individuals of European or Asian heritage were recruited into this study, and 
informed consent was obtained from each subject. Prior to their enrollment in the study, 
subjects were screened at Open Medicine Institute in Mountain View, California. The 
screening included two stages: (1) a questionnaire on health, drug use, and ethnicity as 
well as a cheek swab to determine BCRP Q141K genotype and (2) a blood draw to 
measure complete blood count (CBC), hepatic function (HFP), renal function (RFP), uric 
acid, and HLA-B*58:01 genotype. There were two study designs employed in this study: 
(1) a multi-dose, placebo controlled crossover protocol and (2) a single dose protocol. 
 
Multi-Dose Protocol 
Subjects were asked to come into the clinic for three study days: (1) Placebo phase, (2) 
First Dose of Allopurinol, and (3) their 6th dose of allopurinol. Subjects were given four 
300 mg tablets of allopurinol to take at home once per morning in between the second 
and third study visits.  On each study day, subjects reported to the Open Medicine 
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Institute in Mountain View, California in a fasting state. An initial blood draw was taken 
to establish baseline serum uric acid and creatinine levels and urine was voided at the 
start of the study. Subjects were given a lactose placebo pill for the placebo phase or 
300 mg allopurinol tablet for study visits 2 and 3. A series of blood samples were drawn 
at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-dose. For the final dose of allopurinol 
(3rd study visit), blood samples were also taken 48 and 72 hours post-dose. Serum was 
isolated from blood samples using clotting and centrifugation and stored at -80°C for 
analysis of uric acid, creatinine, allopurinol and oxypurinol content.  Urine samples were 
collected at the following intervals during each study visit: 0-4,4-8,8-10,10-24. The 
volume or urine was recorded for each interval and 20 mL of the urine was then stored 
at -80°C for analysis of uric acid, creatinine, allopurinol and oxypurinol content.  
 
Single-Dose Protocol 
Subjects were asked to come in for a single study visit, following the exact protocol of 
the third clinic visit for the multi-dose protocol. Briefly, subjects came in to the clinic in a 
fasted state, received 300 mg of allopurinol, and were followed up with blood and urine 
draws for 72 hours post-dose.  
 
Analytical Methods for Uric Acid/Creatinine 
Uric acid and creatinine levels were analyzed by Open Medicine Institute according to 
standard spectrophotometry protocol.  
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Analytical Methods for Allopurinol/Oxypurinol 
Allopurinol and oxypurinol were analyzed by Quintara Discovery (Hayward, CA) using 
liquid chromatography tandem mass spectrometry (LC/MS-MS). Samples were diluted 
as needed. An aliquot of 20 µL of serum or urine samples was treated with 200 µL of 
25% Methanol 75% acetonitrile containing internal standard (Fulvestrant). The mixture 
was vortexed on a shaker for 15 minutes and subsequently centrifuged at 4000 rpm for 
15 minutes. The supernatant was transferred to a microtiter plate for the injection to the 
LC-MS/MS. Calibration standards and quality control samples were prepared by spiking 
the test compound into corresponding blank matrix and processed with the unknown 
samples.  The quantification limit was 2 ng/mL for serum and 20 ng/mL for urine.  
 
Clinical Pharmacokinetics 
The pharmacokinetic parameters of allopurinol and oxypurinol were evaluated by non-
compartmental analysis using Phoenix 64 v8.0 (Certara, Princeton, NJ). Samples below 
the lower limit of quantification were excluded from analysis. Area under the curve 
(AUC) was calculated using linear-up, log-down method and elimination constant was 
calculated using slope regression. Exact sample collection times were used for 
pharmacokinetic analysis.  Estimated glomerular filtration rate was calculated from 
serum creatinine levels using the CKD-EPI equation. 
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Fractional excretion was calculated for uric acid and allopurinol/oxypurinol using the 
formula, where Urine Conc and Serum Conc represent concentrations of uric acid, 
allopurinol or oxypurinol in urine and serum, respectively: 
 𝑈𝑟𝑖𝑛𝑒 𝐶𝑜𝑛𝑐.∗ 𝑆𝑒𝑟𝑢𝑚 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑆𝑒𝑟𝑢𝑚 𝐶𝑜𝑛𝑐.∗ 𝑈𝑟𝑖𝑛𝑒 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 
 
Clinical Pharmacodynamics 
Baseline serum uric acid levels were taken as the serum uric acid concentration at the 
zero timepoint just before the subjects’ first dose of allopurinol. The minimum serum uric 
acid during the first 10 hours of allopurinol was then used to calculate the percent 
change from baseline (baseline-minimum/baseline * 100%), the primary 
pharmacodyanmic endpoint.   
 
Statistical Analysis  
Data are expressed as mean ± standard error unless otherwise noted. Unpaired 
student’s t-test was used to analyze the differences in 
pharmacokinetic/pharmacodynamic parameters between genotype groups using a 
dominant genetic model, in which heterozygous and homozygous BCRP Q141K 
subjects were combined. Demographic differences between genotype groups were 
analyzed using ANOVA. The data were analyzed using R v.3.4.0 (27). P-values less 
than 0.05 were considered statistically significant. Graphpad Prism 7.0 (La Jolla, CA) 
was used for visualization.  
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Chapter 4: Conclusions and Perspectives 
 
This dissertation represents an excellent example of reverse translational research, 
which takes a bedside to bench approach wherein findings from studies in human 
subjects are characterized using in vitro and deep phenotyping in vivo methods. Here, 
we focus on allopurinol, the first-line treatment for chronic gout. Specifically, this work 
focuses on identifying the genetic determinants of allopurinol response and 
characterizing these to determine the optimal medication and dosing strategy for gout 
patients.  
 
We performed the largest genome-wide association study (GWAS) to-date centered on 
hypouricemic response to allopurinol, identifying genetic variants in ABCG2, which 
encodes the efflux pump BCRP, as modulators of allopurinol response (Chapter 2). 
While the number of GWAS used to identify genetic factors that underlie diseases or 
other traits has increased along with the sample sizes used in the discovery cohorts, the 
number of pharmacogenetic GWAS remains low in comparison. One of the major 
hurdles that we face in performing pharmacogenetic GWAS is power (1). 
Pharmacogenetic GWAS are typically carried out in small cohorts in comparison to 
GWAS of human disease due to difficulties in assessing drug response phenotypes and 
prescription information, which is frequently unavailable in electronic health records.  
Further, there are often many drug therapies for any given disease.  Thus, the number 
of patients using a particular drug for the treatment of a given disease represents a 
subset of the total patients with the disease.    
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In the study presented in Chapter 2, one of the biggest challenges was defining the 
phenotype and inclusion criteria. While it is tempting to broaden the scope of inclusion 
criteria to include the most patients possible and increase power of detection, we found 
that applying the most stringent inclusion criteria resulted in the most reliable and 
reproducible findings. For example, one of the most important inclusion factors for our 
analysis was the non-adherence rate, or the amount of time that a patient did not have 
medication in hand as determined by prescription refills. Non-adherence can confound 
the effects of genetics on drug response and is not a problem faced when identifying 
genetic determinants of disease risk or anthropomorphic traits.  Because Kaiser 
Permanente Research Program on Genes Environment and Health included 
prescription refill information, we were able to exclude subjects that were non-adherent.  
Unfortunately, electronic health records used by many healthcare systems do not 
include information on prescription drug adherence.   While sampling blood levels of a 
drug is an excellent surrogate for prescription drug adherence in an acute setting, this is 
not a viable solution for longer-term clinical studies.  Thus, the integration of pharmacy 
records with electronic health records in a uniform manner is imperative for the future of 
pharmacogenetic studies so that results may be analyzed and combined across 
healthcare systems (2). 
 
Our enigmatic finding from our GWAS, that BCRP Q141K associated with worse 
response to allopurinol, led to a prospective clinical trial in which we characterized the 
effects of BCRP Q141K on allopurinol pharmacokinetics and pharmacodynamics in 
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healthy volunteers. While we found a statistically significant difference in oxypurinol half-
life in subjects carrying the variant vs. those without, we did not see any significant 
differences in overall exposure or clearance of the drug.  In other words, systemic levels 
of both allopurinol and oxypurinol were not related to genotype of BCRP Q141K.  These 
studies led to us to conclude that tissue levels of allopurinol, which would be expected 
to be affected by BCRP, and not systemic levels of the drug, are the major reason for 
the association of the variant with poor response to the drug.  However, this study was 
the first attempt to characterize how the BCRP Q141K variant may alter response to 
allopurinol.  Clearly, further studies are needed to understand the precise mechanisms 
by which the variant modulates response to allopurinol. 
 
While our clinical study did not offer a full explanation for the association between 
BCRP Q141K and inadequate response to allopurinol, there is no denying that the 
association does exist.  Thus far, the association has been replicated in a number of 
independent cohorts (3-5).  Larger clinical and PK-PD deep phenotyping as well as 
more detailed mechanistic studies may unearth the cause for the association, but these 
trials are costly and labor intensive.  Clearly what is now needed is a guidance for how 
to use the genetic information in the context of other information to select medications 
or improve dosing of allopurinol for the treatment of gout.. For example, increasing 
doses of allopurinol for patients with BCRP Q141K to better control their gout and 
hyperuricemia may be considered a safe option if the recommended doses are within 
the approved range. As prices for genetic tests continue to drop, there is a need for 
patients to be screened for genetic differences in major drug metabolizing enzymes and 
  90 
transporters to make the implementation of pharmacogenetic findings efficient and cost-
effective.  
 
In summary, this dissertation takes an in-depth look at the genetic factors leading to 
inter-individual differences in allopurinol response. Notably, we identified a missense 
variant in a widely expressed efflux transporter, BCRP Q141K, as associating with 
worse response to allopurinol, and characterized the in vivo relationship between this 
variant and allopurinol pharmacokinetics and pharmacodynamics. These findings add to 
the current knowledge of how BCRP Q141K affects the disposition of its substrates, 
further proving that the wide tissue expression of BCRP makes its interactions with drug 
response complex. While larger studies could help further characterize this relationship 
and perhaps offer insight into the treatment of gout overall, genetic screening and dose 
adjustment are affordable and feasible solutions that can be implemented in gout 
patients at risk for suboptimal response.  
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